Louisiana State University Law Center

LSU Law Digital Commons
Journal Articles

Faculty Scholarship

2012

Drug Development--Stuck in a State of Puberty?: Regulatory
Reform of Human Clinical Research to Raise Responsiveness to
the Reality of Human Variability
Michael J. Malinowski
Louisiana State University Law Center, mjmalin@lsu.edu

Follow this and additional works at: https://digitalcommons.law.lsu.edu/faculty_scholarship
Part of the Law Commons

Repository Citation
Malinowski, Michael J., "Drug Development--Stuck in a State of Puberty?: Regulatory Reform of Human
Clinical Research to Raise Responsiveness to the Reality of Human Variability" (2012). Journal Articles.
50.
https://digitalcommons.law.lsu.edu/faculty_scholarship/50

This Article is brought to you for free and open access by the Faculty Scholarship at LSU Law Digital Commons. It
has been accepted for inclusion in Journal Articles by an authorized administrator of LSU Law Digital Commons.
For more information, please contact kreed25@lsu.edu.

FOR EDUCATIONAL USE ONLY
56 St. Louis U. L.J. 363
Saint Louis University Law Journal
Winter 2012
Article
*363 DRUG DEVELOPMENT--STUCK IN A STATE OF PUBERTY?: REGULATORY REFORM OF HUMAN
CLINICAL RESEARCH TO RAISE RESPONSIVENESS TO THE REALITY OF HUMAN VARIABILITY

Michael J. Malinowski [FNa1]
Grant G. Gautreaux [FNaa1]
Copyright (c) 2012 Saint Louis University School of Law; Michael J. Malinowski; Grant G. Gautreaux

Abstract

Scathing critiques of the Food and Drug Administration's (“FDA”) performance by the Government
Accountability Office and Institutes of Medicine, a plummet in innovative new drug approvals in spite of
significant annual investment increases in biopharmaceutical research and development (“R&D”), and
market controversies such as the painkiller Vioxx and the diabetes drug Avandia (both associated with
significantly escalated risks of heart attacks and strokes) have raised doubts about the sufficiency of FDA
*364 regulation. This Article questions how prescription medicines reach the market and proposes lawpolicy reforms to enhance the FDA's science standard for human clinical trials and new drug approvals.
The core message is that relying too heavily on clinical research data generated through the global “gold
standard” of group experimental design--reliance on statistical analysis to compile and compare group
averages--risks predicting little about the actual impact of prescription medicines on individuals,
including members of the groups under study. This Article introduces a law-policy methodology based
upon commercial incentives and intervention by Congress and the FDA to raise the science standard for
human clinical research, and to make drug development more closely parallel the reality of drug delivery
in the practice of medicine. The objectives of this proposal are to promote several pressing needs:
maximize drug performance and minimize adverse events; end the pattern of putting new prescription
medications on the market with too much dependence on the medical profession to introduce
meaningful clinical understanding of drugs through patient use over time; improve biopharmaceutical
R&D decision making; align the regulatory standard with the infusion of added precision associated with
contemporary genetics-based R&D; and realize more sound scientific information directly through the

regulatory process to support the integrity of science in an age of academia-industry integration,
aggressive commercialization, secrecy in science, and constantly, rapidly evolving technology.
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*366 “2007 was the single worst year for new drug approvals in a quarter century and 2008 proved to
be only slightly better.” [FN1]
“[T]he drug industry's research productivity has been declining for 15 years, ‘and it certainly doesn't
show any signs of turning upward’. . . .” [FN2]
“At present, our best advice for anyone concerned with the pharmaceutical treatment of behavior
disorders in people with developmental disabilities is simple: Be skeptical and collect data.”

Introduction

“Emma will never speak” was the conclusion of health care professionals when she was assessed for
significant learning disabilities at the age of three. [FN4] Confirming what her parents had suspected and
feared for much of her life, these health care professionals diagnosed Emma with an autism spectrum
disorder. [FN5] Autism or not, Emma's parents did not accept the notion that their *367 daughter would
never speak, and especially the prognosis that nothing could be done to help her. They researched nonstop and exploited every resource to find appropriate educational support. Their efforts led to entering
Emma into a program staffed by teachers focusing on her particular situation and taking moment-tomoment data on her responses, graphing and analyzing even minute components of her day. Teachers,
working in close collaboration and constantly comparing and analyzing data, used the detailed
information drawn from Emma and several other students clinically very similar to her to generate,
implement, and test--individually and collectively--a litany of highly individualized interventions in an
ongoing manner. Within a little more than one year, Emma acquired some functional speech,
demonstrated learning at increasingly higher rates, showed IQ score improvements, and was
successfully entered into a program that mainstreamed her with children developing according to
“typical” indicators. The interventions--both successful and unsuccessful-- and accompanying, detailed
data were derived from the tactics and strategies in the applied behavioral literature. Most of these
interventions became the subject of a series of publications in the science literature to the benefit of
other teachers, children, and the field in general.
Emma's story illustrates the cumulative effect yielded from single subject research design (“SSRD”),
which entails a systematic implementation of the scientific method to analyze and treat behavioral
problems. [FN6] SSRD, a natural science methodology for human clinical research, developed in practice
and has been addressed in literature for over a half a century in disciplines such as behavior analysis,
education, physical therapy, and occupational therapy. [FN7] *368 With SSRD, evidence-based practices
are identified vis-à-vis replication rather that the aggregate of results en masse. SSRD is an alternative to
group experimental design (“GD”), the global “gold standard” for human clinical trial research in drug
development. [FN8] GD is based in randomized, parallel, group trials. [FN9] While GD typically focuses
on ascertaining statistically significant variations based upon group averages, [FN10] the core SSRD
methodology is to repeat comparisons of control and treatment conditions with the same *369
individual or staggered across similar individuals, graph the data on a subject-by-subject basis, and
analyze the results. [FN11] Thus, the individual serves as her own control while the variables interacting
between the individual and the environment are isolated. Such a finely grained approach enables the
researcher to obtain valuable information about both the individual and the intervention, and more
carefully police threatening complications. This research approach has not been utilized in drug
development: “Although there is a long tradition of employing single subject designs in social science
research, these designs have only recently been utilized in biomedicine.” [FN12]

This Article proposes law-policy reform of human clinical trials in drug development to promote the use
of SSRD. A primary, overarching goal is to advance the transition from traditional pharmaceutical R&D,
with its focus on taking away symptoms, to actually treating the causes of disease--at the cellular,
genetic, and molecular levels. [FN13] Specifically, the Article challenges *370 the FDA's extensive
reliance on the GD model, which has governed clinical research since not too long after enactment of
the Food, Drug and Cosmetic Act in 1938, [FN14] and suggests law-policy reforms to increase SSRD
studies in drug development. A major premise is that regulation of human clinical trials should be
responsive to the governing science, and SSRD emphasizes the reality of human variability [FN15] in a
manner in sync with contemporary genetic science and the actual practice of medicine. [FN16] The core
message is that relying on data generated through GD alone--again, group averages compiled through
statistical analysis to test hypotheses--risks predicting little about the actual impact of prescription
medicines on individual patients at the detriment of ongoing and future drug development, to the loss
of multiple tens of millions of living patients waiting for treatments, who are suffering from ongoing,
seriously debilitating, and even life-threatening human health ailments. [FN17] Such *371 a reliance on
this type of analysis may conceivably mask potentially effective treatments for individuals and lifethreatening complications for others.
A major focus of discussion is the nexus between the regulation of drug development and the delivery of
health care. Under the present law-policy scheme, drug review is too lenient, [FN18] practical yet
sophisticated understanding of new pharmaceuticals is too limited, and market approval invites
excessive off-label use--an approach that muddles clinical care with clinical research excessively, and
exacerbates the unpredictability of prescription medications. [FN19] *372 Ultimately, the medical
profession exercises expansive prescription discretion, on and off FDA-approved labels, to sort through
the actual safety, efficacy, and peculiarities of a drug patient-by-patient, and over time--typically years-after the drug is on the market. [FN20] As documented in one empirical study, “Off-label prescribing is
very common in all areas of medicine. It is not uncommon for a drug to be prescribed more often offlabel than on-label. . . . Indeed, 80 percent to 90 percent of pediatric patient regimens involve at least
one off-label prescription.” [FN21] Ironically, off-label usage has been common practice for individuals
with developmental disabilities and autism, while some physicians do not always recognize applied
behavior analysis as a validated treatment for autism due to the apparent dearth of large scale GD
studies. [FN22]
Congress has recognized and addressed the problem through sweeping legislation known as the Food
and Drug Administration Amendments Act of 2007 (“FDAAA”). [FN23] The methodology of FDAAA is to
“augment premarket clinical studies” and try to cull more from resulting data “with new sources of
evidence about the risks and benefits of drugs,” but the Act does not change *373 reliance on GD as the
gold standard in drug development. [FN24] Rather, the core methodology of FDAAA is to do more with
GD--in essence, to rely on it more. [FN25] Continued over-reliance on GD in human clinical studies
coupled with extensive medical community discretion to essentially experiment on patients without
systematically contributing to the research base--as opposed to clinical researchers experimenting on
research subjects under human subject protections and direct FDA oversight--threatens to perpetuate a

crude working standard for prescription medications as they enter the market and for years thereafter.
This regulatory approach is increasingly unacceptable in an age of genetic science. [FN26]
This Article begins by profiling GD in human clinical trials--again, the so-called gold standard and the
cornerstone of the law-policy rubric governing market approval for human medicinal products. [FN27]
Tremendous reliance on GD has been reinforced globally through the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (“ICH”)
standard sharing. [FN28] Part I then introduces SSRD in an interdisciplinary, comparative manner
through discussion that draws from a debate over GD and SSRD in human clinical studies developed in
another health care context--the field of applied behavior analysis (“ABA”). [FN29] Specifically, the
Comprehensive Application of Behavior Analysis to Schooling Program (“CABAS®”) at Columbia
University's Teachers College has utilized SSRD in research with and treatment of children with
behavioral conditions and often severe learning disabilities, many labeled “autistic,” and, *374 more
recently, neuro-typical children. [FN30] This is a highly protected group under the regulations to protect
human subjects [FN31]--one that has been too often overlooked and avoided in clinical research for
drug development and yet routinely prescribed medications that reach the market. [FN32] CABAS®, with
a legacy of three decades of research and an international network of schools and graduates working in
the field, has challenged the preexisting norms of heavy reliance on GD in clinical research and
generated significant research accomplishments and documented treatment interventions. [FN33] In
addition to the shared context of clinical research, treatment for patients with developmental
disabilities depends heavily--arguably, often too heavily-- on utilization of prescription medicines made
available through the drug development process without data sufficient for physicians to match drugs
and patients. [FN34] These practices, in addition to raising cautionary concerns regarding unknown side
effects, may also lead to an unsubstantiated yet alluring false efficacy.
Part II frames ongoing disappointments and frustrations with contemporary drug development and
challenges the entrenched reliance on GD. Specifically, this Part questions continued dependence upon
mathematical abstracts that, although representative of the group collectively, may say nothing decisive
about members of the group individually, let alone broad populations of patients with health care needs
outside the group. The discussion concludes that the core regulatory process to put drugs on the market
lingers from the past and is disconnected from the patient-centered nature of the practice of medicine
and the science disciplines that dominate today's innovative biopharmaceutical R&D. Part III proposes a
regulatory overhaul of clinical research to modify the gold standard through utilization of SSRD. This
proposal draws from past efforts by Congress and the FDA to shape clinical trial research through both
direct mandates and commercial incentives, *375 including the Best Pharmaceuticals for Children Act
(“BPCA”) [FN35] and the Orphan Drug Act (“ODA”). [FN36]

I. The “Gold Standard” in Human Clinical Research and the SSRD Alternative

The following discussion summarizes the evolution of GD as the gold standard for clinical research and
drug approval with a focus on the accompanying law-policy rubric that promotes it. [FN37] The
discussion then profiles SSRD as an alternative natural science research methodology for human clinical
research that, although increasingly recognized in biomedicine in recent years, remains highly
underutilized in biopharmaceutical R&D. [FN38]
A. The Science and Law-Policy Rubric for Human Clinical Research
The law-policy surrounding human clinical trials reflects the regulatory role the FDA has evolved into
during the decades after enactment of the Food, Drug, and Cosmetic Act of 1938 (“FDCA”). [FN39] The
FDCA bestowed the Agency with the powers to assume a market gatekeeper role--the authority to
examine, question, and evaluate the clinical utility of drugs. [FN40] Still, prior to 1970, the Agency made
law primarily by pursuing judicial enforcement of statutory standards. [FN41] Subsequently, the Agency
has shifted in the direction of an administrative law-policy approach--exercising its capacity as product
reviewer and rule-maker--and has raised the burden on drug sponsors to earn market approval. As
observed by authors Hutt, Merrill, and Grossman, “Faced *376 with increasingly complex substantive
issues and a growing number of firms making regulated products, FDA turned toward rulemaking as the
principal technique for defining legal requirements. The agency attempted to resolve most of the major
issues it confronted through administrative, rather than court, action.” [FN42] The FDA, as product
reviewer and market gatekeeper, has been responsive to clinical trial data of effectiveness generated
through implementation of the GD gold standard--randomized, parallel, group clinical trial designs.
[FN43] The standard has been adopted globally, as recognized by the ICH in E9 Statistical Principles for
Clinical Trials. The ICH issued E9 in 1998 to harmonize statistical methodologies used to support
marketing applications. [FN44] The ICH serves as an advisory body for drug harmonization for the
European Union (“EU”) through the European Medicines Agency (“EMA”), the United States through the
FDA, and Japan through the Ministry of Health, Labor, and Welfare. [FN45] In 2008, the ICH developed
technical requirements for registration of pharmaceuticals for human use. [FN46] The requirements
defined key terms in the discipline of pharmacogenomics, including pharmacogenetics, genomic
biomarkers, and genomic data, and provided sample drug coding categories. [FN47] The intent was “to
develop *377 harmonized approaches to drug regulation” and “to ensure that consistent definitions of
terminology are being applied across all constituents of the [ICH],” as well as the “integration of the
discipline of pharmacogenomics [(“PG”)] and pharmacogenetics into the global drug development and
approval processes.” [FN48] In 2010, the ICH developed requirements for the context, structure, and
format of voluntary biomarker submissions from PG research in order to create a “harmonized
recommended structure for biomarker qualification” that will allow for consistency of applications and
will “facilitate discussions with and among regulatory authorities.” [FN49] Between the three regulatory
entities enveloped in the ICH, all three adhere to these standards, but at this point no standards have
been developed to integrate PG into mainstream healthcare.
The resulting quid pro quo for market access is data generated through GD in four phases (sometimes
classified as five) of clinical trials. [FN50] Phase I trials generally are conducted in tens of healthy
volunteers for up to a month with the objective of making the transition from animal to human

participants through research on toxicity and a showing of safety. [FN51] Minimum doses are
administered, and the healthy status of participants enhances the transparency of their impact. [FN52]
With a focus on safety, the core objective of these trials is to assess the metabolic and pharmacological
actions of the drug candidate in *378 humans, and to identify side effects while increasing doses. [FN53]
Phase I trials also may garner early evidence of effectiveness. [FN54] Phase II trials involve hundreds of
participants drawn from the target disease group and span several months. [FN55] The objectives are to
study the effectiveness of the new treatment, to determine short-term side effects and overall risks
associated with the drug, and to develop advanced dosage criteria. [FN56] Phase III typically
encompasses thousands of disease group participants at multiple sites with the goals of balancing safety
and efficacy, to refine dosage, and establish overall effectiveness against a placebo (sugar pill) or other
control. [FN57]
The data generated in Phase III shapes applications for market access. The baseline standard for market
approval is to outperform a placebo on efficacy, perhaps just by a percentage point or two, with a
showing of tolerable safety in a defined population. [FN58] Once biopharmaceuticals reach the market,
the medical community has broad discretion to use them off-label--and does so aggressively. [FN59] The
FDA continues to regulate pharmaceuticals post-market approval through Phase IV follow-on trials that
probe lingering questions and strive to perfect clinical use, that is, to develop additional details about
the product's safety and efficacy. [FN60] Congress has attempted to shift traditional *379 Phase IV trials
into premarket studies through the FDAAA. [FN61] Phase IV studies have been largely observational and
centered on post-marketing surveillance to detect and define previously unknown or inadequately
quantified adverse reactions and related risk factors. [FN62] In recent years, these studies often have
distinguished defined demographic groups that may have been overlooked as a focus point during the
trials that put the drugs on the market. [FN63] Areas of inquiry may involve formulation evaluations,
dosages, the durations of treatment, and interactions with other medications. [FN64]
A major trend since implementation of the Food and Drug Administration Modernization Act of 1997
(“FDAMA”) has been to err in favor of putting new drugs on the market on a watch-and-see basis to
introduce access for patients in need, albeit conditioned with follow-on studies--often referred to as
506B studies. [FN65] This approach is consistent with expansion of the FDA's mission under FDAMA to
include efficiency, along with efficacy and safety, for new drug approvals. [FN66] Unfortunately, the FDA
has been lax in enforcing these post-market study conditions. [FN67]
*380 FDA regulations and standards for clinical trial study design distinguish exploratory trials from
confirmatory trials and hold the former to more rigid standards. [FN68] With the most common study
design, parallel group experimental design, participants are randomized to one or more trial arms, and
each arm is allocated a different treatment. [FN69] Ideally for the purposes of generating and collecting
data both for safety and efficacy, GD comparisons are drawn between a group of participants taking the
drug candidate and another administered a placebo to show statistically significant differences between
group mean scores. [FN70] Double-blinding (neither the administering physician nor the participants
know who actually is receiving the drug candidate) is used to check the risk of bias. [FN71] However, in
practice, it tends to be much more complicated to incorporate participants' access to existing
treatments into the studies. Research subjects are administered the drug candidate coupled with an

existing standard-of-care treatment. [FN72] Comparisons are made with groups *381 given the standard
treatment alone or, where there are multiple treatment options, the drug candidate with varied
couplings. [FN73]
Since the introduction of the Prescription Drug User Fee Act in 1992 (“PDUFA”), the FDA has been
granting accelerated approval of novel drugs based upon surrogate endpoints--laboratory measures that
suggest improvements in patient health rather than factual documentation of actual impact given a
contained timeframe--in accordance with formal clinical standards, meaning patient health
improvements. [FN74] Inferences about the drug candidates are based on statistical comparisons of
group mean scores. [FN75] The ultimate compilation is a statistical common denominator across the full
target disease population.
A major limitation in GD for drug development is that human variability among study participants may
prove significantly more substantial than anticipated even though, symptomatically, the subjects appear
to share what has been classified a disease. [FN76] The mathematical abstract derived from the
population may predict nothing for any individual participant. As explained by Professor Janosky,
[P]atients are unique and may not respond similarly to various treatments, and in those instances a
randomized clinical trial design may be inappropriate. *382 Guidelines are established from the
averaged study findings, which may not necessarily be applicable when evaluating suitable treatment
options for individuals. Specifically, patients treated in primary care settings may differ clinically from
patients in the clinical trial, the patient diversity in the clinical trial may not generalize to certain patient
populations, and the stringent trial criteria for accepting participants may not accurately reflect general
patient populations. [FN77]
The effort to account for human variability and to generate a meaningful predictor of drug performance
through GD, to the extent that is possible, demands thousands of participants at multiple locations--a
need that has increased substantially over the last decade and pushed drug sponsors to outsource both
toxicology studies and human clinical trials to contract research organizations (“CRO”). [FN78] “In the
past, a single phase three trial might have needed 3,000 patients and cost between $10 million and $20
million. Today, the same kind of study would take 20,000 patients and cost $50 million to $100 million . .
. .” [FN79] While the trend is expansion of clinical trial recruitment outside of the U.S. borders, [FN80]
“[t]he number of clinical trials in the United States has climbed dramatically in recent years. Between
2000 and 2006, *383 clinical trials increased from 40,000 to 59,000--a nearly 50 percent jump.” [FN81]
Though industry is spending unprecedented amounts on clinical research and conducting more and
larger clinical trials, the sobering outcome is a steep drop in innovative new drug approvals in recent
years. [FN82]
Congress has recognized and responded to the drug development dilemma by forcing more of GD
through the FDAAA and culling more data around it rather than questioning the methodology. [FN83]
The current administration is concerned enough to introduce a billion-dollar center, funded in a time of
economic trouble, to infuse government-performed research assistance in order to help industry put
more new drugs on pharmacy shelves. [FN84]

B. The Advent and Evolution of SSRD
SSRD is a natural science research methodology developed in practice and addressed in literature for
over a half a century in disciplines such as behavior analysis, education, physical therapy, and
occupational therapy. [FN85] “Although there is a long tradition of employing single subject designs in
social science research, these designs have only recently been utilized in biomedicine,” [FN86] and
“these methods have been used infrequently in clinical psychopharmacology.” [FN87] However, the
cross-discipline popularity of SSRD is on the rise: “In recent literature, it appears these designs are
receiving more recognition, as they are being increasingly employed in research across disciplines.”
[FN88]
The core SSRD methodology is to repeat comparisons of control and treatment conditions with the same
individual or staggered across similar individuals, graph the data on a subject-by-subject basis, and then
analyze the resulting data. [FN89]
*384 Single-case design experiments to evaluate treatment effects involve directly observing and
measuring one or more specific behaviors of an individual repeatedly for a period of time while a
particular treatment is not in place (the control or baseline condition), and while it is (the experimental
or treatment condition). . . . Comparisons of control and treatment conditions are repeated, or
replicated, with the same individual and/or with other similar individuals. [FN90]
Human variability is accounted for in single subject research by manipulating environmental variables
that occasion steady states of responding--rather using statistical analysis to herd subjects into what are
declared to be steady states for the individual, but actually represent only group averages. Specifically,
In applied single-case studies, the interest is not in statistically significant differences between group
mean scores but in clinically and educationally important improvements in individual behavior in
comparison to baseline. In many behavior analytic studies, those changes--that is, differences in data
from the control and treatment conditions--far exceed what is required for statistical significance.
Individual differences in responses to treatment and variability in behavior are not viewed as “noise” to
be wiped out mathematically, but as natural features of behavior to be studied further so they can be
better understood. Replication, which is an essential ingredient of science, is built into single-case
designs. . . . The evidence for those conclusions comes from conditions where the treatment and other
variables are tightly controlled and the effects of the treatment on behavior are observed directly,
rather than from statistical transformations of numbers that do not represent actual behavior. [FN91]
The SSRD and GD methodologies for responding to variability in outcomes are fundamentally different.
[FN92] In GD, researchers typically use large samples to average out differences in outcomes, while
SSRD researchers attempt to bring outcome differences under experimental control--in other words,
statistical control over error through large samples under GD, versus experimental control to reduce
error with a heightened focus on individual subject responses under SSRD. [FN93] As pointed out by
Professor Janosky,

[The GD] strategy is problematic for two reasons: (1) statistical power and sample size are related, with
larger samples at times leading to significant but very small effects with little pragmatic value and (2) it
discourages the researcher from strategically modifying treatment (i.e., response guided
experimentation) that may positively impact most if not all the patients. [FN94]
*385 In contrast, under SSRD, patient responsiveness is probed through modification of, and changes in,
the treatment as a consequence of response-guided experimentation. [FN95]
Ultimately, the objective driving drug development must be the improvement of patient health. The
medical community effectively engages in a simulation of SSRD through often creative patient-bypatient treatment with biopharmaceuticals under its discretion to use them off-label--a “cart before the
horse approach” so to speak. In the words of some thoughtful observers, “[t]o some extent, clinical
medicine always has been tailored to the patient in that each physician-patient relationship is unique,
and each clinical encounter represents the physician's attempt to provide the optimal care to the
patient in the examining room, the emergency room, the hospital bed, and the intensive care unit.”
[FN96]
SSRD's focus on the individual has made the methodology a natural fit for the field of behavior analysis.
[FN97] In fact, much of the groundwork is attributable to B.F. Skinner and dates back to the 1930s:
Skinner emphasized studying the individual to determine lawful models of behavior. He drew heavily
upon animal research, often using pigeons or rats, to uncover fundamental learning principles that could
then be applied to humans. Inevitably, similar procedures for modifying behavior were applied to
individual human subjects. Within the realm of applied behavior analysis, single subject design studies
began examining methods for modifying behavior of individuals with diverse psychological problems,
including stuttering, learning disabilities, mental retardation, and psychotic symptoms. [FN98]
SSRD has had a profound impact in the treatment of individuals with autism spectrum disorder and
other severe learning disabilities. [FN99] For example, the CABAS® model, a comprehensive approach to
behavior analysis and schooling, [FN100] has yielded an abundance of procedures, tactics, interventions,
and large scale protocols for parents, educators, and children with a wide *386 variety of disabling
conditions. [FN101] The underlying theme of all CABAS® research is adhering to scientific rigor based on
John Stuart Mill's five canons of the scientific method. [FN102] Through tightly controlled scientific
studies conducted by practitioners, CABAS® research has promoted the growth and development of
academic social repertoires for children, and generally enabled learning and function in thousands of
children deemed “unteachable.” [FN103] While education is a field susceptible to trends, untestable
theories, and heavy reliance on construct attributes, SSRD has allowed the field of behavior analysis to
establish grounded, effective approaches and documented success with severely learning-disabled
children through natural science evaluation in human clinical research. Interestingly, while SSRD
methods have been developed through and used significantly in ABA, they have been used infrequently
in clinical psychopharmacology.

II. Drug UnderDEVELOPMENT

Throughout much of the twentieth century and into the present one, pharmaceutical research and
development (“R&D”) has been the most profitable sector. [FN105] For decades, our tendency as
patients and consumers has been to believe that prescription medications improve human health and,
in turn, to associate medicine closely with science--especially when grappling with a seriously
debilitating illness. [FN106] There have been profound improvements to human health through
pharmaceuticals for well over a half century, [FN107] but the overall reality is that the prescription
medication arsenal to treat all human ailments prior to the 1990s consisted of merely 2000-3000
commercial pharmaceuticals derived from 483 drug targets (compounds that serve as the basis for
medicinal applications). [FN108]
*387 A. The Twentieth Century Drug Development Experience
The crudeness of the underlying science relied upon is self-evident in the twentieth century drug
development experience. Historically, developers would sort through thousands of drug targets to
produce just one pharmaceutical success. [FN109] The endeavor focused on taking away the symptoms
of disease--not on understanding and treating the causes of disease. [FN110] “[D]rug discovery
essentially was a linear process based upon screening and testing of thousands of chemicals and natural
substances for potential therapeutic activity. Screening was time consuming and largely random
because drug targets and drug functions were in most cases unknown.” [FN111] Compounds were
introduced in living organisms to identify their effect and potential medicinal utilities, purified to control
toxicity in conjunction with at least one medicinal use, and introduced onto the market with the
expectation that physicians would experiment further while practicing medicine on patients and identify
additional clinical utilities through off-label uses. [FN112]
Drug sponsors were not even required to demonstrate efficacy for market access until 1962. [FN113]
The regulatory standard for market approval of a drug candidate in the United States has been
eliminating symptoms, even if just marginally more effectively than a placebo, coupled with a showing
that adverse events and other safety issues across the target disease population are tolerable given the
benefits. [FN114] This standard, paired with the discretion of *388 commercial sponsors to tailor clinical
research and to apply (or not) for approval of specific uses in applications for market access, has invited
tremendous off-label use by the U.S. medical profession once products reach the market. [FN115]
Though the biopharmaceutical sectors spend tens of billions of dollars on research annually, [FN116]
they spend more on marketing--both legal and illegal. [FN117] Much of their marketing is directed at
encouraging the medical community to exercise its discretion to use their products off-label. [FN118]
Off-label use is motivated further by publication of industry-sponsored research in science and medical
journals, direct-to-consumer marketing, [FN119] and patient faith in new treatments, including
experimental ones. [FN120] Even when marketed legally, only “[o]ne-third of all drugs act as expected
when prescribed to patients,” and there are approximately two million adverse drug reactions requiring

hospitalization each year. [FN121] Adverse drug reactions cause more than *389 100,000 deaths
annually in the U.S.--meaning that more people in the U.S. die from legal use of prescription medications
than from automobile accidents. [FN122] Medicine remains much more art than science:
Even today, with a high-tech health-care system that costs the nation $2 trillion a year, there is little or
no evidence that many widely used treatments and procedures actually work better than various
cheaper alternatives.
....
. . . And while there has been progress in recent years, most of these physicians say the portion of
medicine that has been proven effective is still outrageously low--in the range of 20% to 25%. [FN123]
B. Today's Drug Research and Development Potential
Drug development has changed fundamentally. [FN124] The legacies of discretion to commercial
sponsors over the content of clinical research and to the medical community over off-label use are
prevalent today, but the science of drug development has evolved and is undergoing a genomics
(genetic expression) metamorphosis--a “genomics revolution.” [FN125] The prevalence of
“biopharmaceuticals” in the drug development pipeline and the centralized review of all new drugs,
whether based primarily in biology or chemistry, within the Center for Drug Evaluation and Research
(CDER) beginning in 2004 [FN126] confirm that pharmaceutical R&D and biotech have integrated
extensively. [FN127]
*390 The potential of ongoing drug development, with a map of the human genome in hand [FN128]
and the creation of more profound tools underway, [FN129] arguably is limited only by human ingenuity
given increasing abilities to manipulate the “highly sophisticated, delicate regulatory pathways and *391
feedback loops” [FN130] of drug targets through the precision of genetics and identification of
environmental influences. [FN131] Today holds the promise of infiltrating disease pathways on the
cellular, genetic, and molecular levels to treat the causes of disease and thereby improve human health
well beyond existing capabilities. [FN132]
The completion of the human genome map in 2003 made it possible to identify an individual's genetic
makeup to determine disease risk, and a patient's likely response to certain medications. Genetic
information may be used to diagnose a condition in an individual prenatally or prior to the presentation
of any clinical symptoms. [FN133]
Millions of associations have been made between genetic variations and human health, and each
constitutes a potential drug target. [FN134] Increasingly, discussion of a forthcoming era of personalized
medicine--engineering medications tailored to individual patient's genetic makeup (pharmacogenetics,
developed through pharmacogenomics) [FN135]--and extensive genetic profiling as part of both
preventive care and treatment carries a tone of “when” rather than “if.” [FN136] Overall, there is
considerable consensus that “the availability of the *392 human genome sequence, together with the

pharmacogenomic and pharmacogenetic approaches to developing new drug therapies, has and will
continue to contribute to a better selection and faster development of safer and more effective
diagnostics and treatments.” [FN137] Affirmations of the health care potential of contemporary
biopharmaceutical R&D include Herceptin, [FN138] Gleevec, [FN139] and Olaparib. [FN140]
C. Drug Disappointments and Desperation
Unfortunately, the present reality is that drug development lingers between the scientifically crude, yet
enormously profitable pharmaceutical past and the biopharmaceutical present and future. [FN141] “Ten
years after President Bill Clinton announced that the first draft of the human genome was complete,
medicine has yet to see any large part of the promised benefits.” [FN142] The transition could take
many years--decades according to some commentators. [FN143] In recent years, drug development
disappointments have vastly outnumbered successes in spite of tremendous investment. [FN144]
According to the pharmaceutical industry's trade organization, the Pharmaceutical Research and
Manufacturers of America (“PhRMA”), “In 2009, America's pharmaceutical research and biotechnology
companies continued to make the *393 world's largest investment in pharmaceutical R&D, holding
steady with $65.3 billion spent on R&D, including $45.8 billion by PhRMA members alone.” [FN145]
Nevertheless, new drug approvals fell to a twenty-five year low in 2007, just eighteen, followed by a
slight bump to twenty-four in 2008 and twenty-six in 2009. [FN146] In 2010, Pfizer Inc., the world's
largest research-based pharmaceutical company, did not produce a single new drug approval. [FN147] In
comparison, new drug approvals peaked in 1996 when the FDA approved fifty-three. [FN148] According
to Dr. Francis Collins, Director of the National Institutes of Health, this decline in productivity over the
past fifteen years “certainly doesn't show any signs of turning upward.” [FN149] In fact, the federal
government has become concerned enough about the performance of the commercial
biopharmaceutical sectors to start a “billion-dollar government drug development center to help create
new medicines.” [FN150] Industry continues to spend enormous amounts of money to make new drugs.
[FN151]
The drop in new drug approvals has taken place in spite of annual governmental investments of billions
of dollars in biomedical research and a substantial increase in commercial investment in
biopharmaceutical R&D. “Before 1980, the National Institutes of Health (NIH) funded most medical
research. . . . Today, drug and medical device companies fund up to 80% to 90% of all clinical trials; in
2005, industry invested 78% more in research and development than did the federal government.”
[FN152] Though the trend is to export clinical research beyond the U.S. borders and to outsource it to
CROs, [FN153] the amount of clinical research undertaken today within the United States is
unprecedented-- an almost fifty percent increase during the first half of this decade. [FN154] Phase III
trials have expanded to 20,000 subjects from just *394 3,000 five years ago, which has doubled their
cost--now typically $50-100 million. [FN155]
In addition to the decline in new drug approvals, many of the prescription drugs the FDA has put on the
market in recent years have proven disappointing. There is ample reason to question their quality and
the Agency's performance overseeing them. [FN156] Most notably, Vioxx has become a “scarlet letter”

the FDA is likely to wear for years to come, [FN157] and many additional prescription drug problems
have followed in recent years. In the fall of 2010, the FDA itself “concluded that in some cases two types
of drugs that were supposed to be preventing serious medical problems were, in fact, causing them.”
[FN158] These were Avandia, prescribed heavily to treat type-2 diabetes, and bisphosphonates--an
active agent in the prescription drugs Fosamax, Actonel, and Boniva--used widely to prevent fractures
common in people with osteoporosis. [FN159] Avandia was associated with an increased risk of heart
attacks and strokes, a major problem for its target patient group given two thirds of diabetics die of
heart problems, [FN160] and bisphosphonates was *395 determined to actually cause fractures of the
thigh bone and degeneration of the jawbone. [FN161] In addition, a whole generation of teenagers with
severe acne was treated with Accutane, on the market in 1982, which now is associated with
inflammatory bowel disease, ulcerative colitis, Crohn's disease, other gastrointestinal disorders, liver
damage, birth defects, and suicidal thoughts. [FN162] Roche, the manufacturer, pulled Accutane from
the market on June 29, 2009. [FN163] Many commercial drug developers and their supporters blame
the FDA for the drop-off in new drug approvals, claiming the FDA has been too strict. [FN164] Others
attribute the fall to an industry that is clinging to the low science and regulatory standards of the past,
stretching the commercial lives of pharmaceuticals through manipulation of the patent system, and
contriving “me too” drugs rather than engaging in genuine innovation. [FN165] When the Vioxx
controversy substantiated doubts about the FDA's reliability in regulating the biopharmaceutical market,
[FN166] the Agency responded by raising *396 its level of scrutiny, which has generated substantial drug
sponsor demand for specialized toxicology studies by CROs. [FN167] In fact, Vioxx and related concerns
about FDA effectiveness inspired inquiry and generated corroborating reports on deficiencies from the
Government Accountability Office (“GAO”), the Institutes of Medicine (“IOM”), and congressional
hearings. [FN168] These *397 questions about the sufficiency of drug regulation and overall agency
performance prompted FDA Commissioner Margaret Hamburg, when newly appointed, to establish a
task force with the mission of developing recommendations to increase transparency of the Agency's
activities and decision-making. [FN169]
Avandia illustrates a trend that accompanied modernization of the Agency through the FDAMA:
conditional market access with reliance upon post-marketing studies for safety and efficacy assurances.
[FN170] With the introduction of user fees under the PDUFA [FN171] and modernization through
FDAMA, [FN172] the Agency has approved drugs based upon surrogate endpoints-- indications that the
drug performs, rather than definitive proof--and conditioned upon follow-on clinical studies. [FN173]
Sixty-four drugs reached the market conditionally between 1992 and 2008. [FN174] According to the
GAO, the FDA has allowed drugs to stay on the market even when follow-up studies showed they did
not save lives. [FN175] Although more than one-third of these conditional studies are pending, the FDA
never has pulled a drug from the market because of a failure to do required follow-up about actual
benefits--even when the information is *398 more than a decade overdue. [FN176] This failure is
consistent with GAO and IOM declarations that the FDA's performance post drug approval is
substandard. [FN177]
The very integrity of contemporary drug science has been called into question. Arguably, “government
interventions are necessary to protect and preserve the public nature of science, which is essential to

shore up the contemporary science enterprise.” [FN178] Aggressive integration of academia and
industry has created a proliferation of conflicts of interest, and the public nature of science--collegiality,
communication, transparency, and accountability--has shifted in the direction of secrecy. [FN179] In the
words of one observer, “It has turned universities into commercial entities, created a multibillion-dollar
industry of technology transfer, and subsidized virtually every biotechnology company and discovery of
the past twenty-five years.” [FN180] The science publications depended upon for scrutiny,
accountability, and human health assessment have also embraced commercialization--evident by
conflicts of interest controversies and the journals' imposition of high cost barriers to access their
publications: [FN181]
*399 The vast capacity to publish research and to share knowledge is tainted by conflicts of interest
which threaten the reliability and integrity of the peer review process and, consequently, the underlying
research. Governments, professional societies, and most science journals have failed to introduce and
enforce the mechanisms necessary to manage conflicts of interest in an era of aggressive
commercialization with meaningful confidence.
Also, industry has directly increased its influence over government and the general public substantially
over the last few decades. [FN182] PDUFA legislation, [FN183] direct interface between industry and the
broader government through extensive lobbying, [FN184] and direct communication with the general
public through billions of dollars invested in marketing annually have raised concerns and inspired calls
for more regulation. [FN185]

III. Law-Policy Alchemy: A Proposal to Change the Science Standard in Human Clinical Research from
Gold to Platinum

The FDA science standard for drug approval and the law-policy implementing it are, at best, dangerously
dated--to the detriment of drug development, the practice of medicine, and human health. [FN186]
Nevertheless, the commercial interests vested in new drug development, domestic and international,
are too influential and too wedded to GD for an expansive break from the past to be a realistic
possibility in the foreseeable future. [FN187] Under PDUFA, which generates the salaries of more than
900 FDA reviewers through the collection of user fees, industry has tremendous ongoing negotiation
leverage given the inclusion of five-year sunset provisions in each PDUFA renewal coupled with two
decades of FDA financial dependence for a considerable portion of its new drug review operating
budget. [FN188]
Arguably, wholly uprooting the entrenched science standard, even if this were a viable option, would
not be desirable given the approximately fifteen-*400 year timeline to develop each innovative new
drug and the transitional nature of ongoing science in the drug development pipeline. [FN189] Such a
major change, especially if forced through law-policy that imposes more clinical trial obligations, could
chill investment in pharmaceutical R&D, which is sorely needed during this time of historically high drug

development costs, product disappointments, and economic challenges that extend well beyond the
biopharmaceutical sectors. [FN190]
Although drug development is evolving in the direction of precision through genomics (genetic
expression), [FN191] proteomics (protein expression), [FN192] and related fields, overall, the endeavor
still remains too crude to adopt SSRD as a substitute for traditional GD. [FN193] As observed by the
FDA's Janet Woodcock, an agency leader under several presidential administrations, both Democratic
and Republican, “At this time, medical practice is predicated on observation. For example, we still
collectively categorize lung cancer as we did one hundred years ago. We still are not sophisticated. We
don't know what the actual molecular cause of that particular cancer is in that particular person because
we don't look for it.” [FN194] However, the biopharmaceutical sectors certainly have the resources and
capabilities to rise to the occasion of a higher standard in clinical research than traditional GD. [FN195]
*401 A meaningful, pragmatic transition is needed: SSRD should be introduced as a complement or
nested research methodology to GD to shift more meaningful understanding of pharmaceuticals from
clinical care (the delivery of health care to patients) to clinical research; to lessen experimentation on
patients in the delivery of their care through physician off-label use, which is removed from regulations
to protect human subjects; [FN196] and to infuse responsiveness to the increasing precision enabled in
both drug development and the delivery of care by contemporary genetic science. [FN197] “For
biomedical *402 researchers, the best course for increasing scientific understanding of relevant
phenomena revolves around the utilization of a variety of methodological designs, with the research
question of interest determining the choice of the design.” [FN198] Although meaningful SSRD data
could complicate GD trials and lengthen the drug approval process, understanding pharmaceuticals
much more before they reach the market is sorely needed. [FN199] Moreover, it is a cost that could be
contained through incremental implementation and potentially offset through a reduction in the lost
opportunities attributable to drug underdevelopment. Although SSRD presumably would narrow the
existing opportunity to oversell by making new drugs more thoroughly understood prior to their market
entry, the extra data could raise the presently waning confidence of providers and patients--a “one-two
punch” of science. From a regulatory perspective, infusing more specificity into the product approval
process, knowing much more about pharmaceuticals prior to putting them on the market, and,
consequently, restricting the familiar level of off-label use are desirable and needed--and demanded
increasingly by government policy makers and the general public. [FN200]
The following discussion establishes the potential of SSRD to improve drug development and health care
delivery, with emphasis on the practicality and feasibility of incorporating SSRD into human clinical
research. After identifying law-policy options, the Article emphasizes the use of positive commercial
incentives based upon enacted legislation that has succeeded in getting desired human clinical trial
research undertaken by industry--namely the BPCA and the ODA, each of which is addressed in the
following discussion.
A. SSRD's Potential to Improve Drug Development and Delivery

Wait-and-see dependence on the medical profession to sort out the impact of prescription medications
on individuals, one patient at a time, in a trial-and-error manner, “exposes patients to potentially
harmful drug interactions and *403 delays potentially effective or the ‘right’ treatment.” [FN201] As
recognized by Dr. Janosky, an expert in SSRD, there is a strong parallel between SSRD and the actual
delivery of health care:
In a primary care setting, the patient generally exhibits symptoms and the physician follows evidencebased or appropriate steps to treat these symptoms. The physician evaluates the patient's history, signs,
symptoms, medical test results, and examines the patient, and subsequently implements a treatment or
intervention if warranted. . . . In primary care settings, standardized procedures are employed that
include objective measurement of the outcomes, such as systolic blood pressure measurements. These
design and intervention procedures are analogous to the standardized procedures used in single subject
research designs, such as testing the effectiveness of a medication over a course of time. [FN202]
SSRD, the very nature of which is close scrutiny of each of the individuals under study, [FN203] could
improve decision-making during the clinical trial process and actually increase flexibility in clinical
research for drug development because it presents an opportunity to tailor interventions for specific
subjects and to modify ineffective ones over the course of the period of study. [FN204] A major practical
advantage of SSRD over GD is that “[i]t overcomes some of the inherent limitations found in large-scale
clinical trials, in that treatments are tailored for unique individuals and can also be modified over time.”
[FN205] SSRD data could better enable sponsor decision-making for its GD counterpart, thereby saving
them from investing hundreds of millions of dollars in the development and marketing of products like
Vioxx, Avandia, and Accutane, each of which has exposed their manufacturers to substantial product
liability and class action lawsuits. [FN206] By addressing human variability through SSRD, drug sponsors
could cut back significantly on the time and expense of human clinical trials that are required to put new
drugs on the market, both of which have risen significantly in recent years. [FN207] Moreover, there is
an obvious ethics advantage in that many SSRD designs ensure that *404 each individual receives the
treatment(s) and does not require denying patients access to potential treatments to create a control--a
standard component of GD. [FN208] SSRD could even enable research not practicable under GD.
[FN209] As explained by Professor Janosky,
Specifically, at times it is difficult to find a large number of patients who have unique demographics or
suffer from rare diseases. Furthermore, large N studies can be time consuming. One of the
consequences of the time consuming nature of large N research is the difficulty in studying public health
crises, for example. Additionally, the exorbitant financial costs of large-sample research often limit who
is able to conduct such projects, at times risking an ethical dilemma with the linking of the researcher
and the funder in mutual vested interests in the results. For example, funding from pharmaceutical
companies is often needed to conduct the multi-million dollar research necessary for evaluating the
same drugs those companies produce. [FN210]
SSRD, with its emphasis on responsiveness to human variability, offers an opportunity to identify genetic
markers and to develop meaningful biomarker screens during the human clinical trial process.
Specifically, SSRD introduces an opportunity to use the clinical trial process to develop a bouquet of

sophisticated genetic screens--for example, genetic tests that stratify patients in the trials to discern
those most prone to responsiveness and those at higher risk for adverse events, and perfecting drug
dosage on a person-by-person basis. [FN211] Genetic differences impact responses to pharmaceuticals,
and at times do so profoundly. [FN212] Studies establish that enzyme variations in genes, with thirty or
more enzymes typically coded for each gene, may have a profound impact on the rate that they are
metabolized--a major consideration for what constitutes safe and effective dosing for individual
patients. [FN213] A noted illustration is the wide variation in patient reactions to asthma medications,
*405 some of which studies have attributed to identified differences in genetic makeup. [FN214]
B. The Feasibility of SSRD in Drug Development--Precedent and Practice
Several trends suggest that drug sponsors should expect more scrutiny and demands for accountability
from regulators, the medical community, and the general public: rising health care finance pressures,
federal and state, domestic and international; increased transparency of market performance and
market behavior through internet communication, including organized observation through patient and
consumer protection groups; and pressure on the FDA to increase post-marketing regulation
requirements and general enforcement. [FN215] SSRD could prove a means to meet and quell these
pressures, and implementation is practicable: there is precedent for the use of SSRD in human clinical
research to advance health care, albeit almost entirely outside of the context of biopharmaceutical
development. [FN216]
Extensive SSRD human clinical research has been done in applied behavior analysis and education,
[FN217] and “[n]umerous studies have highlighted the importance of the single subject design paradigm
in primary care.” [FN218] Some especially notable disease-related group accomplishments utilizing SSRD
include a large portion of the research studying treatments for aphasic patients (loss of the ability to
articulate ideas or comprehend language due to brain damage from injury or disease), attention deficit
hyperactivity disorder (“ADHD”), and diabetes. [FN219] Many SSRD studies in the primary care setting
have been premised upon raising the predictability of responsiveness to stimulant medications at
various dosages, including an ambitious collective assessment study carried out in Australia more than
two decades ago. As summarized by Professor Janosky,
[I]n the 1980s, McMaster University designed a service for community and academic physicians to
facilitate the planning and conduction of single subject (N-of-1) trials. The effectiveness of the trials was
evaluated by the physicians' management plans and confidence levels in the plans both prior to and
following trials. A total of 57 single subject trials were completed, with 50 trials providing a definite
clinical answer and 15 resulting in the physician *406 altering patient treatment. In those 15 trials
resulting in treatment adjustment, 11 trials lead to physicians discontinuing the medication therapy they
planned to administer indefinitely. Trials that were not completed generally stemmed from patient' or
physician' noncompliance or patient' concurrent illness [sic].

Based upon these results reported by the collaborative team at McMaster University, single subject
trials afford important opportunities for application in biomedicine, including directly improving patient
clinical care. [FN221]
SSRD experience in human clinical trials and in the primary care context over decades could be infused
into drug development readily, creatively, and with flexibility, as demonstrated by Professor Gina Green:
Unlike between-groups studies, single-case studies can be conducted in typical service settings like
schools, treatment centers, hospitals clinics, and homes. Their focus on the development of individual
behavior and their flexibility makes these methods especially well-suited for studying treatments for
[autism spectrum disorders], given the large individual differences among people with those diagnoses.
Single-case research methods also afford a means for practitioners as well as researchers to evaluate
the effects of many types of treatments--behavioral, educational, medical, or combinations--with
scientific rigor. [FN222]
A report issued by the IOM in 2001, which provided initial guidelines for small clinical trials, is an
affirmation of the feasibility and potential utility of SSRD in drug development. [FN223] The report
recognized the potential utility of these trials for a portfolio of situations, including rare diseases, unique
study populations, individually tailored therapies, isolated environments (for example, health care in
rural areas), emergency situations, and public health urgency. [FN224]
An SSRD component to clinical trials for drug development would introduce several potential benefits, in
addition to raising fundamental understanding about new drugs during the pre-market clinical research
stage. The size and costs of GD trials have increased immensely in concert with the proliferation of the
genetic sciences and associated precision--which by its very nature demands increased attention to
human variability. [FN225] The GD approach is demonstrating decision-making confusion and clinical
trial *407 failures. [FN226] As observed in an April 2010 report issued by the Institute of Medicine,
approximately forty percent of all advanced clinical trials sponsored by the National Cancer Institute,
organized under the GD gold standard for the most part, are never completed--resulting in a waste of
money, effort, and lost opportunities to improve human health and reap financial returns. [FN227]
An obvious primary question for implementation of SSRD is, given industry's entrenched commitment to
GD, how to use SSRD and GD together in drug development. Johnston and Pennypacker, authors of a
heavily-cited text on behavioral research that compares and contrasts SSRD and GD, propose that,
where both are used, SSRD should be utilized to graph and check data for each subject as a quality
control on GD reliance on inferential statistical techniques and interpretation to generate and explain
data. [FN228] In fact, they believe that all data should be subjected to SSRD scrutiny before it even is
eligible for use in GD. [FN229] Their primary concern is that group data risks obscuring individual
patterns of responding:
[T]he more an analytical procedure changes the investigator's picture of the subject's behavior as it
actually happened, the greater the risk that the analytical procedure may exert more control over
interpretations than do the data. . . .

A related guideline may be stated as follows: The more an investigator has to change the data to see
something important, the greater the risk that the result is not that important or, perhaps, not even
there. [FN230]
To begin the transition into utilization of SSRD in biopharmaceutical R&D, [FN231] one option is to
pursue running SSRD and GD trials in parallel and throughout Phases I-III of the pre-market human
clinical trial process. [FN232] Incorporating the Johnston and Pennypacker approach, SSRD trials could
be started in advance and used to shape GD trials, and then as a quality control *408 throughout their
duration. [FN233] Another possible approach would be to use SSRD more intensely in a focused
capacity--perhaps for specific trials, specific patient subpopulations, or for specific treatments, such as
those for rare patient populations in conjunction with the Orphan Drug Act. [FN234] Specifically, “single
subject designs may be nested within larger clinical trials to increase compliance and answer more
detailed questions. Single subject designs are particularly useful for answering questions regarding rare
diseases, side effects, unique populations, emergency situations, and isolated environments, in which
between-group designs would be unfeasible or impractical.” [FN235]
Another option, and one that could be applied in conjunction with the others, would be to introduce
SSRD services to assist physicians with market use of prescription drugs as an extension of Phase IV
trials--an application strongly supported by the McMaster University study and ample primary care
applications. [FN236] In summary,
Research supports the effectiveness of the single subject design, from studying treatments for rare
patient populations to providing N-of-1 trial services in assisting physicians. The single subject design is
an innovative addition to the arsenal of available methodologies for primary care physicians, biomedical
students, residents, medical research faculty, clinical practitioners, among others. Consistent with the
NIH Roadmap Initiative, increasing awareness of the utility in the single subject design could enhance
treatment approach and evaluation both in biomedical research and primary care settings. [FN237]
*409 C. Law-Policy Catalysts to Turn Gold into Platinum
Although “there is substantial proof that the current method of creating medicines for the general
public is problematic and could prevent effective treatments from reaching the marketplace” , [FN238]
voluntary uptake of SSRD by drug developers is unlikely. They are inclined to resist the official addition
of SSRD into the regulatory process for the same reason they have been slow to introduce
pharmacogenomics data (R&D based upon genetic expression [FN239]) in their applications in spite of
FDA encouragement--fear that it will be used against them to limit their market reach. The FDA has
issued voluntary guidelines to promote submission of pharmacogenomics data which, in sync with SSRD,
innately involves closer individual patient scrutiny--including at the genetic and molecular levels--and
more extensive patient-centered data compilation during the clinical trial process. [FN240]
Unfortunately, the guidelines *410 have not overcome industry fear that genetic specification will break
down disease groups and restrict market reach through narrower approvals, more defined product

labels, reimbursement limitations, and less physician discretion to use these pharmaceuticals off label.
As explained by Dr. Woodcock,
The primary policy problem right now is that most of these genetic tests are not being evaluated in
clinical studies, and they are not being seen by the regulatory agencies. Application in the official drug
development regulatory process is stymied by concern about how these tests will be used by the
marketing application reviewers. This could present a real lost opportunity for any person who wants to
take medicine in the foreseeable future. [FN241]
Even when pharmacogenomics data make it onto drug labels, [FN242] the underlying sponsor data
released is limited, and the medical community often lacks the knowledge to make efficient use of it.
[FN243]
A thoughtful law-policy intervention beyond voluntary guidelines is essential to add a meaningful SSRD
component to drug development. Using the regulatory process to attempt to impose commercial uses
on new drug candidates or specific types of human clinical trials on drug developers would invite
allegations of undue impediment on the commercial freedom that is the touchstone of our private
market system and introduce susceptibility to legal *411 challenges. [FN244] The drug development
regulatory regime embodies deference to commercial free speech, proprietary interests, profit
incentives, and the discretion to practice medicine--as the FDA has been reminded by Congress and
through several legal challenges during the genomics revolution. For example, the House Report that
accompanied FDAMA expressly states that “the FDA has no authority to regulate how physicians
prescribe approved drugs in the context of their medical practice. Physicians prescribing off-label uses of
approved drugs is not within the jurisdiction of the FDA.” [FN245] As for legal challenges, in 2000 the
U.S. Court of Appeals for the District of Columbia dismissed a challenge to FDAMA provisions addressing
manufacturer promotion of off-label use that claimed the provisions imposed an undue burden on
commercial free speech in violation of the First Amendment. [FN246] However, the Court based its
decision on the fact that the parties reached agreement that there was no longer an issue after the FDA
changed its stance. [FN247]
Perhaps the most vivid recent illustration of the limits of agency authority to force studies on drug
sponsors is the FDA's attempt to fill the vacuum of pediatric studies for pharmaceuticals known to be
prescribed to children. [FN248] In *412 fact, even today, pediatric data is insufficient, at times wholly
lacking, for two-thirds of prescription drugs. [FN249] A 1994 study reported that six of the ten drugs
most commonly prescribed to children had inadequate pediatric labeling, [FN250] which inspired the
FDA to issue a rule and to introduce a voluntary, incentive-based program to promote pediatric testing
and labeling. [FN251] The tone during this time, under David Kessler who was the FDA Commissioner
from 1990 to 1997, was administrative caution:
I need to acknowledge the limits of FDA's authority. It is our job to review drug applications for the
indications suggested by the manufacturer. We do not have the authority to require manufacturers to
seek approval for indications which they have not studied. Thus, as a matter of law, if an application
contains indications only for adults, we're stuck.

To address this dearth of pediatric data even for drugs prescribed to children routinely, Congress
codified a voluntary, incentive-based five-year program through a pediatric exclusivity provision in
FDAMA. [FN253] This program granted drug manufacturers six months of market exclusivity for their
products--as opposed to just extending intellectual property rights--as an incentive for conducting
pediatric studies. [FN254] The FDA then went further and issued a “Pediatric Rule” in 1998 that
mandated pediatric testing-- both for drug candidates and those already approved for market use.
[FN255] The FDA was *413 sued successfully under the Administrative Procedure Act [FN256] with
claims that promulgation of the Pediatric Rule was arbitrary and capricious and exceeded the FDA's
authority. [FN257] The voluntary program worked but was only moderately successful. As of April 2001,
the FDA had issued a mere 188 written requests covering 155 drugs already on the market and just
thirty-three new drugs not yet approved. [FN258] “As of April 1, 2001, only 28 drugs had been granted
periods of exclusivity.” [FN259] Most of these drugs did experience a labeling change of some degree to
address pediatrics, but, according to an article published in 2001, only 37.5 percent constituted a
significant change in safety or dosing. [FN260] By discussions in 2001 to reauthorize the voluntary
program, only twenty-five percent of drugs had been studied in children--just a five percent increase
from the 1994 statistic. [FN261]
While the litigation against the FDA rule was pending and the FDAMA voluntary program approached its
January 1, 2002, sunset, [FN262] Congress intervened with the Best Pharmaceuticals for Children Act.
[FN263] BPCA reinstated the FDAMA voluntary program for pediatric testing with the incentive of six
months of market exclusivity and then went further by empowering the FDA to step over manufacturer
resistance and get pediatric trials done by third parties through the National Institutes of Health or with
funding from a federal trust. [FN264] BPCA also provided a basis to strike the FDA's Pediatric Rule.
[FN265] Regarding the BPCA's effectiveness, critics have *414 pointed out that the BPCA approach
shifted considerable drug development cost from manufacturers to taxpayers. [FN266] Nevertheless, as
of March 2004, pharmaceutical manufacturers had issued 346 requests to evaluate prescription drugs
for pediatric use, ninety-seven drugs were granted six months of exclusivity, and new labels were
approved for seventy. [FN267] As of 2008, 145 drugs had been issued exclusivity. [FN268]
Another illustration of the success of Congress and the FDA to utilize positive commercial incentives to
get desired clinical research undertaken in drug development is the Orphan Drug Act. ODA is a rewardsbased program that makes it commercially viable to develop drugs for small groups of patients through
tax incentives, a seven-year period of market exclusivity, and other benefits. [FN269] The targeted
research is being done: some 350 orphan drugs have been approved in the U.S. market alone, and the
program has been replicated by other countries. [FN270] Orphan drug filings have increased, especially
submissions from multinational pharmaceutical sponsors. There is considerable overlap between the
ODA methodology and suggestions from NIH and others to incorporate small clinical trials and SSRD into
drug development with an initial focus on small, discernible patient groups.
The effectiveness of commercial incentives to get desired clinical research done has been demonstrated
through ODA and BPCA, as has the *415 ineffectiveness of soft incentives such as voluntary guidelines
and the susceptibility of FDA mandates to legal challenge. To implement SSRD into drug development as
quickly, effectively, and pragmatically as possible, Congress and the FDA should build upon what has

worked and an opportunity introduced by a new government initiative--introduction of a federal
research center with the specific mission of helping industry overcome drug development difficulties.
Given the commonality between ODA--small, distinguishable disease groups--and SSRD, ODA should be
modified to favor utilization of SSRD in program qualification and provide additional incentives for its
use, including additional tax incentives, additional reviewer support and responsiveness, and an
additional extension (at least one year, to make the total exclusivity eight years) of market exclusivity for
approved products that complete SSRD studies. The FDA would have the discretion, as it does with the
base ODA program, to set criteria and determine eligibility--meaning the Agency could experiment with
SSRD to assess its efficacy in varied applications.
For drug development beyond the small disease groups that qualify for ODA status, Congress and the
FDA should draw heavily from BPCA--perhaps in a manner that, in addition to promoting SSRD overall,
particularly favors use of SSRD in pediatric studies and studies of other distinguishable patient and
disease groups to make up for the relative dearth of data over the years. This approach would be closely
consistent with the suggestions of SSRD experts in disciplines that have embraced the approach,
including professors Green, Janosky, Johnston, and Pennypacker. [FN271] SSRD studies should be
solicited with the incentive of at least six months of additional market exclusivity for resulting products
(pediatric studies with SSRD would be rewarded with a year or more of product exclusivity), and
Congress should create a separate trust fund to enable the FDA to undertake these studies when
industry sponsors refuse. The fund should be established to direct the FDA to include post-marketing
(Phase IV) studies with primary care physicians on both new and existing drugs to assist physicians with
market use--along the lines of the McMaster University study and suggestions of Dr. Janosky. [FN272]
Both the IOM and GAO have determined that the FDA does a grossly insufficient job once
pharmaceuticals reach the market and recent experience with the disappointment of approved drugs
confirms, suggesting that SSRD studies, consistent with the practice of medicine, could make a
substantial contribution. [FN273] An SSRD fund would impose a cost on taxpayers--a major *416
criticism of BPCA. [FN274] Nevertheless, the state of drug development, new drug disappointments, the
potential of SSRD coupled with genetic precision to improve drug development and benefit health care,
the need to lessen dependence on years of physician off-label use for meaningful understanding of new
drugs, consumption of government regulatory resources for this disappointing return, and lost product
opportunities for sectors that are a major presence in our economy suggest that taxpayer investment in
such a fund would be more than justified--especially given the amount of funding taken from industry in
user fees to cover FDA operations. The federal government appears to have recognized as much through
establishment of a billion dollar center to help industry create new drugs, headed by Dr. Francis Collins
who led the U.S. government HGP effort and now is Director of NIH. [FN275]
This center to assist drug development also should make SSRD a priority. Although the Center is focused
primarily on basic research--for example, to use its state-of-the-art robotic screening capabilities to
identify chemicals that influence enzymes--and animal studies, its mission also includes starting human
trials. [FN276] The center should broaden its clinical research vision and include SSRD. The transition
into clinical research in drug development involves a substantial increase of industry investment-money, research, and opportunity. Contingent upon the outcome of research, investment correlates

with industry commitment--meaning an inclination to want to work with the center to resurrect
troubled drug development efforts that hold market potential. The center, preferably working in
conjunction with the FDA, could infuse SSRD to salvage developed drug R&D undertakings representing
substantial time and research investments and financial investments of tens, if not hundreds, of millions
of dollars. The Center's involvement in just Phase I trials could make significant contributions. [FN277]

Conclusion

The so-called gold standard for human clinical research in drug development, GD, no longer glitters--to
the extent it ever really did. The costs of relying too heavily on GD are self-evident, including a
significant decline in new drug approvals in spite of historic investment and resources such as the map
of the human genome, drug disappointments such as Vioxx and Avandia that have threatened the lives
of the patients taking them and generated large *417 class action law suits, and dwindling faith in the
FDA as evident in the passage of the FDAAA in 2007 as well as the GAO and IOM reports issued in 2006.
[FN278]
The crude science past in drug development, which may have justified reliance on GD, no longer should
control the genetics present and future of human clinical research in biopharmaceutical R&D and FDA
market approval. Genetics is increasingly dominating the drug development pipeline, and the very
nature of genomics is unprecedented scientific precision--working at the cellular, genetic, and molecular
levels in living organisms to identify genetic expression, to reveal the origins and progression of disease,
and to make connections between the two and develop drugs based upon those connections. [FN279]
Regulatory reform is needed to make the science standard for human clinical trials responsive to the
significance of human individuality and variability--factors recognized innately in both genomics and the
patient-centered practice of medicine.
This Article has proposed law-policy reforms to infuse an alternative science methodology into human
clinical research for drug development--SSRD. SSRD shares the responsiveness of genetics-based R&D to
the reality of individual human variability, and an SSRD complement to GD could prove a means to move
drug development through its present state of puberty between the crude science past and geneticsbased future. [FN280] “The single subject design has been successful in illuminating research findings
across a variety of disciplines. It overcomes some of the inherent limitations found in large-scale clinical
trials, in that treatments are tailored for unique individuals and can also be modified over time.” [FN281]
The proposals to promote SSRD put forth in this Article are based upon commercial incentives and
programs that have endured the threat of legal challenges--the ODA and the BPCA. [FN282] The FDA has
successfully used ODA and BPCA to get needed clinical research done on small disease groups and
children that industry had avoided. This Article also proposes to infuse SSRD into human clinical research
through a billion-dollar government center recently established to help industry create new drugs.
[FN283] The objective, as expressed by NIH Director Francis Collins who will direct the center and

headed the U.S. government's effort to map the human genome, is to convert contemporary genetic
science accomplishments into clinical applications that *418 improve human health and move industry
out of its fifteen year slump in new drug approvals. [FN284]
The biopharmaceutical sectors have the resources and capabilities to meet a higher science standard in
clinical research than GD--a standard that has resulted in ongoing drug underdevelopment. [FN285]
SSRD is an opportunity to introduce a gold standard that actually glitters in an age of genomics and shifts
drug development in the direction of needed improvements to human health.
[FNa1]. Michael Malinowski is the Ernest R. and Iris M. Eldred Professor of Law, Paul M. Herbert Law
Center, Louisiana State University. He received his J.D. from Yale Law School, where he was an Articles
Editor for the Yale Law Journal, and his B.A., summa cum laude, from Tufts University.
[FNaa1]. Dr. Grant Gautreaux, Assistant Professor, Department of Teacher Education, Nicholls State
University, received his Ph.D. in Applied Behavior Analysis (ABA) from Columbia University Graduate
School of Arts and Sciences. He is board-certified by both CABAS® (Comprehensive Applied Behavior
Analysis in Schools) and the BACB (Behavior Analyst Certification Board), and he is a CABAS® Assistant
Research Scientist and Senior Behavior Analyst. The authors would like to thank Dr. Doug Greer, founder
of CABAS®, for engaging discussion about his “platinum standard” for clinical trials and encouragement
to write this Article, and the Jigsaw School in England for the opportunity for both authors to observe
the application of SSRD to educate a group of children with severe learning disabilities over several years
of progress. This Article was selected by peer review for presentation at the 9th International
Conference on Health Economics, Management and Policy, in Athens, Greece, in the summer of 2010,
and the 5th International Social Science Research Conference, held in New Orleans, Louisiana, in
September 2010. The authors appreciate the input of these event organizers, which enriched their
efforts, and thank Professors Neville M. Blampied and Dolleen-Day Keohane for their reviews, helpful
comments, and other input. Gratitude also is extended to John P. Torbitzky and his colleagues at the
Saint Louis University Law Journal for their excellent work. An international extension of this Article,
which builds upon the discussion presented here to directly promote acceptance of the single subject
research design in clinical research by Europe and the International Conference on Harmonisation is
forthcoming. See Michael J. Malinowski & Grant G. Gautreaux, All That Is Gold Does Not Glitter in
Human Clinical Research: A Law-Policy Proposal to Brighten the Global “Gold Standard” for Drug
Research and Development, 45 Cornell Int'l Law J. (forthcoming 2012).
[FN1]. G. Steven Burrill, Polishing the Crystal Ball: G. Steven Burrill Predicts What's Ahead for Biotech in
2009, Burrill Report (Jan. 2, 2009), http://www.burrillreport.com/article-980.html. The FDA approved
eighteen innovative new drugs in 2007, twenty-four in 2008, and twenty-six in 2009. Ed Silverman, How
Many New Drugs Did FDA Approve Last Year?, Pharmalot (Feb. 18, 2011, 9:35 AM),
http://www.pharmalot.com/2011/02/how-many-new-drugs-did-fda-approve-last-year; New Drug
Approvals on Pace to Exceed 2008 Total, Res. Recap (June 9, 2009),
http://www.alacrastore.com/blog/index.php/2009/06/09/new-drug-approvals-on-pace-to-exceed2008-total. But see Miho Nagano, Big Pharma Looks for a Fix, Investor's Bus. Daily, Sept. 29, 2008, at A9

(stating seventeen approvals in 2007). See infra notes 146-49 and accompanying text.
[FN2]. Gardiner Harris, A New Federal Research Center Will Help to Develop Medicines, N.Y. Times, Jan.
23, 2011, at A1 (quoting Dr. Francis S. Collins, Director of the National Institutes of Health, in a story on
the federal government's decision to launch a billion-dollar drug development center to help industry
create new pharmaceuticals).
[FN3]. Alan Poling et al., Pharmaceutical Interventions and Developmental Disabilities, in Developmental
Disabilities: Etiology, Assessment, Intervention, and Integration 105, 120 (W. Larry Williams ed., 2004).
Poling's article also states that:
Few, if any, psychotropic drugs have been adequately evaluated in people with developmental
disabilities, despite repeated calls for further research.... As in years past, further research is needed to
produce data that will guide physicians in accurately matching drugs to patients.... The use of single-case
research methods may make it easier to conduct research, although these methods have been used
infrequently in clinical psychopharmacology.
Id. at 119.
[FN4]. This case study is derived from Dr. Gautreaux's work with children diagnosed with severe learning
disabilities. “Emma” is a fictional name, and identifiers have been excluded to protect the family's
privacy. Similar anecdotal and scientific accounts have been published. See, e.g., Catherine Maurice, Let
Me Hear Your Voice 11-25 (1993).
[FN5]. See Am. Psychiatric Ass'n, Diagnostic and Statistical Manual of Mental Disorders 66-67 (4th ed.
1994) (describing the diagnostic features of “Autistic Disorder”).
[FN6]. SSRD is explained infra at Part I.B. For illustrations of SSRD see, Janine E. Janosky et al., Single
Subject Designs in Biomedicine 81-95 (2009). “The single subject design is a family of designs that share
fundamental concepts and methodologies.” Id. at 9. It is important to note that the literature often
commingles single subject studies with “N-of-1” (“number-of-one”) trials, which may be trials literally
involving a single subject. Most SSRD experiments involve focused studies of and between multiple
participants. Gina Green, Single-Case Research Methods for Evaluating Treatments for Autism Spectrum
Disorders, 8 Speaker's J. 69, 73-74 (2008) (describing the SSRD method). For additional background
information on SSRD and scientific research methods generally, see David H. Barlow et al., Single Case
Experimental Designs: Strategies For Studying Behavior Change (3d ed. 2009) (discussing the origins of
SSRD and detailing SSRD methods and issues); Murray Sidman, Tactics Of Scientific Research: Evaluating
Experimental Data In Psychology 2 (1960) (discussing important points in evaluating scientific research);
B.F. Skinner, The Behavior of Organisms: An Experimental Analysis (1938) (providing the foundation for
modern-day behavior analysis); John Carey, Medical Guesswork: From Heart Surgery to Prostate Care,
The Health Industry Knows Little About Which Common Treatments Really Work, Bus.Wk., May 29,
2006, at 72 (discussing the benefits believed to be provided when using “evidence-based” medicine).

[FN7]. See Robert H. Horner et al., The Use of Single-Subject Research to Identify Evidence-Based
Practice in Special Education, 71 Exceptional Child. 165, 165-66 (2005); see also John O. Cooper et al.,
Applied Behavioral Analysis 201 (2d ed. 2007) (describing multiple baseline design as a research tactic
for evaluating treatment effects in behavior analysis); J. M. Johnston & H. S. Pennypacker, Strategies and
Tactics of Behavioral Research 296-309 (2d ed. 1993) [hereinafter Johnston & Pennypacker, Strategies
and Tactics] (discussing SSRD and GD in the context of behavior analysis); J. M. Johnston & H. S.
Pennypacker, Readings for Strategies and Tactics of Behavioral Research 3-7 (2d ed. 1993) [hereinafter
Johnston & Pennypacker, Readings] (discussing behavior analysis as a natural science); Alan E. Kazdin,
History of Behavior Modification: Experimental Foundations of Contemporary Research (1978) (tracing
the history of experimentation in behavior modification, a field that leans heavily on SSRD type
methodologies); Steven C. Hayes, Single Case Experimental Design and Empirical Clinical Practice, 49 J.
Consulting & Clinical Psychol. 193 (1981) (arguing that SSRD is a good fit for clinical psychology); Mark
Wolery & Susan R. Harris, Interpreting Results of Single-Subject Research Designs, 62 Physical Therapy
445 (1982) (discussing the interpretation of SSRD results in the context of physical and occupational
therapy); infra Part I.B. For thoughtful guidance on the use of SSRD in applied psychology, see Neville M.
Blampied, Single-Case Research and the Scientist-Practitioner Ideal, in APA Handbook of Behavior
Analysis (Gregory J. Madden ed., forthcoming 2012) [hereinafter Blampied, Single-Case]. For a tutorial
on SSRD, see Neville M. Blampied, Univ. of Canterbury, Single-case Research: Useful Tools for 21st
Century Applied Science, Address at the Society for the Quantitative Analyses of Behavior 34th Annual
Meeting (May 28, 2011) (PowerPoint presentation on file with the Saint Louis University Law Journal)
[hereinafter Blampied Presentation]. A video of Professor Blampied's tutorial presentation is available at
http://www.sqab.org/tutorials.php.
[FN8]. Janosky et al., supra note 6, at 81-82; see infra note 42-43, 86-88 and accompanying text.
[FN9]. Janosky et al., supra note 6, at 81; see infra note 43 and accompanying text.
[FN10]. See infra Part I.B (offering a comparative discussion of GD and SSRD). Although averages may be
compiled based upon the mode (a variable that occurs the most frequently), the mean (the total
occurrence divided by the number of subjects), or the median (the occurrence in the lies in the middle)
of a group under study, group design generally centers on determining statistically significant variations
between the group that is receiving the treatment and those that are not. See Alan Poling et al.,
Fundamentals of Behavior Analytic Research 161-62 (1995); William W. Rozeboom, Good Science is
Abductive, not Hypothetico-Deductive, in What If There Were No Significance Tests? 335, 335-38 (Lisa L.
Harlow et al. eds., 1997) (discussing the pitfalls of significance testing); Stephen T. Ziliak & Deirdre N.
McCloskey, The Cult of Statistical Significance 123-130 (2008) (detailing and criticizing the rise of
statistical significance in psychology research);. Statistical formulas are derived to account for
complexity, but they are based upon these averages. Rozeboom, supra. Interestingly, “[a]veraging
across individuals had its origins in a philosophical/religious attempt to remove the effects of original sin
from measurement of humans.” Blampied Presentation, supra note 7, at 27.

[FN11]. Green, supra note 6, at 74; Janosky et al., supra note 6, at 81; David L. Morgan & Robin K.
Morgan, Single-Case Research Methods for the Behavioral and Health Sciences 27-30 (2009); Jaan
Valsiner, Where is the Individual Subject in Scientific Psychology?, in The Individual Subject and Scientific
Psychology 11 (Jaan Valsiner ed., 1986). SSRD is discussed in detail infra at Part I.B. For an excellent,
accessible summary of SSRD methodology, see generally Blampied Presentation, supra note 7. For
discussion of SSRD in the context of applied psychology, see Blampied, Single-Case, supra note 7.
[FN12]. Janosky et al., supra note 6, at 81; see also Green, supra note 6, at 69.
[FN13]. See infra Part II.B. This Article focuses on human clinical trials, not basic (“bench”) studies.
Reflective of the vast complexity and dynamism of human genetics--an estimated 23,000 genes
responsible for all human variability, and the intense, ongoing interface of genes and environmental
factors in human health--and the nascent state of genetic science at this time, there is tremendous
dependence on group studies at the very beginning of the drug development continuum. American
Health Lawyers Association's Advisory Council on Racial and Ethnic Diversity, Patient-Tailored Medicine
Part One: The Impact of Race and Genetics on Medicine, J. Health & Life Sci. L., Oct. 2008, at 1, 7
[hereinafter Patient-Tailored Medicine Part One]; American Health Lawyers Association's Advisory
Council on Racial and Ethnic Diversity, Patient-Tailored Medicine, Part Two: Personalized Medicine and
the Legal Landscape, J. Health & Life Sci. L., Jan. 2009 at 1, 5-7 [hereinafter Patient-Tailored Medicine
Part Two]. A rough map of the human genome determined “active” was completed just years ago
(2003), and efforts to purify that map and to fully decode the human genome are still underway. Human
Genome Project Information, U.S. Dept. of Energy, http://www.ornl.gov/sci/techresources/Human_
Genome/home.shtml (last updated July 25, 2011). Now scientists in the field of epigenetics are studying
the “other human genome”--heritable changes in gene function that occur without a change in DNA. See
Gary Felsenfeld, A Brief History of Epigenetics, in Epigenetics 16 (C. David Allis et al. eds., 2007); Adrian
Bird, Perceptions of Epigenetics, 447 Nature 396, 396 (2007); see generally James A. Goodrich & Jennifer
F. Kugel, Binding and Kinetics for Molecular Biologists (2007) (discussing qualitative measurements of
biological binding reactions, “which are the fundamental building blocks of all complex biological
systems”). For a richer discussion of the genome, see Eric H. Davison, The Regulatory Genome: Gene
Regulatory Networks in Development and Evolution (2006). For further discussion of epigenetics, see
the articles contained in Epigenetics, 293 Sci. 1063-106 (2001), and NOVA: Epigenetics (PBS television
broadcast July 24, 2007), available at http:// www.pbs.org/wgbh/nova/sciencenow/3411/02.html. In
sum, at the base level of genetic science, comparisons are made between multiple individuals at the
genetic level, at times entire populations (“biobanks”), to sort through this vast universe of variables and
identify points for study. See generally Symposium, Regulation of Biobanks, 33 J.L. Med. & Ethics 1
(2005) (offering articles discussing biobanks and biobanking issues); Symposium, Proceedings of “The
Genomics Revolution? Science, Law and Policy”, 66 La. L. Rev. (Special Issue) 1 (2005) [hereinafter
Genomics Revolution] (offering articles discussing the necessity for biobanking to meet the needs of
genomics research); see also Michael J. Malinowski, Law, Policy, and Market Implications of Genetic
Profiling in Drug Development, 2 Hous. J. Health L. & Pol. 31 (2002) (noting the law, policy, and market
implications of pharmacogenomics). Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring
Drugs to Fit Patients' Genetic Profiles, 43 Jurimetrics J. 1, 7-11 (2002) (discussing the potential for

pharmacogenomic research to enhance pharmaceutical therapies). Therefore, this Article appreciates
the distinction between genetic studies at the molecular level from human clinical trials to treat
individuals, and the discussion centers on the latter. Comparing the utility of GD and SSRD at the base
level of drug development is beyond the scope of this Article.
[FN14]. “The first of the so-called miracle drugs, Sulfanilamide, led to the adoption of the Federal Food,
Drug, and Cosmetic Act of 1938 which emphasized premarketing safety of drugs, based on scientifically
designated animal and clinical studies.” Steven E. Pegalis, American Law of Medical Malpractice § 17:13
(3d ed. 2005).
[FN15]. It is important to note that, while “human variability” is assumed and considered innate to
humans in group experimental design, in SSRD human variability is considered external and is able to be
controlled by accounting for extraneous variables. See infra Part I.B.
[FN16]. See Patient-Tailored Medicine Part One, supra note 13, at 7: see generally Genomics Revolution,
supra note 13 (offering articles discussing contemporary genetic science and issues in genomics).
Genetic specificity in contemporary biopharmaceutical R&D is addressed infra at Part II.B.
[FN17]. As observed by other commentators in the context of patient-tailored medicine and race-based
genetics research:
To predict therapeutic outcomes in individual patients, drug makers rely on statistical analyses of a
targeted population's response to the medication in question. Thus, a practitioner's choice of drug often
is based on population averages. Therefore, the current method of developing drug therapy focuses on
large patient populations as groups, irrespective of the potential for individual, genetically-based
differences in drug response.
Patient-Tailored Medicine Part One, supra note 13, at 7. The extent to which drug sponsors have been
permitted to generalize over human variation in clinical research is extraordinary. For example,
throughout most of the twentieth century, women and children typically were excluded from the groups
studied to bring many of our familiar pharmaceuticals to market--including pharmaceuticals for
conditions that impact women and children, such as asthma and heart disease. See Sarah K. Keitt, Sex &
Gender: The Politics, Policy, and Practice of Medical Research, 3 Yale J. Health Pol'y L. & Ethics 253, 253
(2003). The rationale was to work to avoid groups deemed “protected” under federal regulations to
protect human subjects--including women, the unborn, and children--and subject to more scrutiny,
coupled with failure to appreciate the hormonal and other biological differences between men and
women, adults and children, or the strategic choice to avoid complicating trials with factors such as the
female hormonal cycle, menopause, and puberty. Id. at 254-55; Karen H. Rothenberg, Gender Matters:
Implications for Clinical Research and Women's Health Care, 32 Hous. L. Rev. 1201, 1206-10 (1996).
Accordingly, out of necessity, doctors prescribed medicines on the market to treat women and children
in spite of a dearth of data about those uses. For example, the doses for children have been adjusted at
doctor discretion based upon weight--similar to veterinary practice today. See Barbara A. Noah, Just a

Spoonful of Sugar: Drug Safety for Pediatric Populations, 37 J.L. Med. & Ethics 280, 281-82 (2009). The
1993 NIH Revitalization Act requires inclusion of women in Phase III clinical studies and gender-based
analysis of research results. National Institutes of Health Revitalization Act of 1993, Pub. L. No. 103-43,
§131, 107 Stat. 122, 133-35 (codified at 42 U.S.C. § 289a-2 (2006)). The Best Pharmaceuticals for
Children Act (“BPCA”) codified patent extension incentives for drug sponsors to include children and
created a trust fund for the FDA to do the same when drug sponsors refuse--conducting its own trials
directly or through contracted third parties. See Best Pharmaceuticals for Children Act, Pub. L. No. 107109, 115 Stat. 1408 (2002) (codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.).
[FN18]. In addition to the limitations of GD addressed throughout this Article, the efficacy standard for
market approval based upon that data is to be better than a placebo or sugar pill, meaning to be better
than nothing. See infra note 58 and accompanying text.
[FN19]. See infra Part III.A. Congress has responded to the problem, but this Article questions its fix
through the Food and Drug Administration Amendments Act of 2007 (“FDAAA”) because of the ongoing
fundamental reliance on GD. See infra notes 23-25 and accompanying text. “[N]either Congress nor the
FDA has attempted to regulate the off-label use of drugs by doctors and consumers. A physician may
prescribe a legal drug to serve any purpose that he or she deems appropriate, regardless of whether the
drug has been approved for that use by the FDA.” Wash. Legal Found. v. Henney, 202 F.3d 331, 333 (D.C.
Cir. 2000). Off-label use of pharmaceuticals is generally accepted in the medical community and
commonly practiced. Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51, 56 (D.D.C. 1998), vacated in
part on other grounds sub nom. Wash. Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir. 2000) (observing
that “off-label use of FDA-approved drugs by physicians is an established aspect of the modern practice
of medicine”); see Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341, 350 (2001) (noting that off-label
use of medication is not only accepted in the medical community, but a “necessary corollary of the
FDA's mission to regulate ... without directly interfering with the practice of medicine”).
[FN20]. The same often is true with new medical devices and procedures. An illustrative example of this
point is the debate over when women should have mammograms. After decades of relying upon group
numbers to strongly encourage all women over the age of forty years to have mammograms annually,
the U.S. Preventive Services Task Force, based upon actual patient experience with the technology, now
discourages the presumption and emphasizes the importance of a case-by-case, physician-patient,
individualized approach. Danielle Dellorto, Task Force Opposes Routine Mammograms for Women Age
40-49, CNN Health (Nov. 16, 2009), http://articles.cnn.com/2009-1116/health/mammography.recommendation.changes_1_routine-mammograms-mammography-taskforce?_s=PM:HEALTH. For more information on the task force and its projects, see U.S. Preventive
Services Task Force, U.S. Dept. of Health & Human Serv., http://www.ahrq.gov/clinic/uspstfix.htm (last
visited Dec. 29, 2011).
[FN21]. Daniel B. Klein & Alexander Tabarrok, Do Off-Label Drug Practices Argue Against FDA Efficacy
Requirements? A Critical Analysis of Physicians' Argumentation for Initial Efficacy Requirements, 67 Am.

J. Econ. & Soc. 743, 744, 755 (2008). As observed by these authors, “Most cancer and AIDS patients are
given drugs that are not FDA certified for the prescribed use. In a large number of fields, a majority of
patients are prescribed at least one drug off-label.” Id. at 744 (citations omitted).
[FN22]. See Poling, supra note 3, at 119-20; Autism Spectrum Disorders: Treatment Options, Nat'l Inst.
of Mental Health, http:// www.nimh.nih.gov/health/publications/autism/treatment-options.shtml (last
updated July 22, 2009). Off-label use is extremely pervasive in pediatrics, and data for the
pharmaceutical treatment of behavior disorders in people with developmental disabilities is grossly
insufficient. See Klein & Alexander, supra note 21, at 755; Poling, supra note 3, at 119-20.
[FN23]. Pub. L. No. 110-85, 121 Stat. 823 (codified as amended in scattered sections of 21 U.S.C.).
[FN24]. Barbara J. Evans, Seven Pillars of a New Evidentiary Paradigm: The Food, Drug, and Cosmetic Act
Enters the Genomic Era, 85 Notre Dame L. Rev. 419, 420, 434 (2010) [hereinafter Evans, Seven Pillars].
For a thorough discussion of the FDAAA, see id., and Barbara J. Evans, Authority of the Food and Drug
Administration to Require Data Access and Control Use Rights in the Sentinel Data Network, 65 Food &
Drug L.J. 67 (2010) [hereinafter Evans, Authority].
[FN25]. See Evans, Seven Pillars, supra note 24, at 425.
[FN26]. For discussion of the impact of genetic science on drug development methodology and the
associated potential to raise precision, see infra Part II.B.
[FN27]. See supra notes 8-9 and accompanying text.
[FN28]. Several guidances for clinical trials originally developed by the ICH have been adopted by the
FDA and published in the Federal Register. See, e.g., International Conference on Harmonisation;
Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583 (Sept. 16, 1998); International
Conference on Harmonization; Good Clinical Practice: Consolidated Guideline, 62 Fed. Reg. 25,692 (May
7, 1997); see generally ICH Guidance Examines Statistical Principles to Support Clinical Research, Guide
to Good Clinical Prac. Newsl. (Thompson Publishing Group, Inc., Wash., D.C.), Nov. 1998, at 5, available
at 6 No. 2 CLINPRAC-NWL 5 [hereinafter ICH Guidance Examines]. For general information about the
ICH, visit its official website, http://www.ich.org (last visited Dec. 29, 2011).
[FN29]. See Cooper et al., supra note 7, at 201-24 (discussing a popular research method in applied
behavior analysis); Johnston & Pennypacker, Readings, supra note 7, at 16-17; Johnston & Pennypacker,
Strategies and Tactics, supra note 7, at 296-309.
[FN30]. R. Douglas Greer & Dolleen-Day Keohane, A Real Science and Technology of Education, in
Evidence-Based Educational Methods 23, 37-38 (Daniel J. Moran & Richard. W. Malott eds., 2004)
[hereinafter Greer & Keohane, Real Science]; R. Douglas Greer et al., The Effects of the Verbal
Developmental Capability of Naming on How Children Can Be Taught, 1 Acta De Investigación

Psicológica 23, 26-27 (2011); R. Douglas Greer & Dolleen-Day Keohane, The Evolution of Verbal Behavior
in Children, Behav. Dev. Bull. 31 (2005), reprinted in 1 J. Speech Language Pathology & Applied Behav.
Analysis 111, 112-13 (2006).
[FN31]. 45 C.F.R. §§ 46.401-.409 (2010) (establishing children as one of the protected groups within
overall human subject protection regulations). For discussion of the absence of children in drug
development research, see infra notes 248-268.
[FN32]. See supra note 17.
[FN33]. See Greer & Keohane, Real Science, supra note 30, at 37-41.
[FN34]. See supra note 17; Poling, supra note 3, at 119.
[FN35]. Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, 115 Stat. 1408 (2002) (codified as
amended in scattered sections of 21 U.S.C. and 42 U.S.C.).
[FN36]. Orphan Drug Act, Pub. L. No. 97-414, § 2, 96 Stat. 2049, 2049-51 (1983) (codified as amended in
scattered sections of 21 U.S.C. and 42 U.S.C.).
[FN37]. See infra notes 43-44, 92-94 and accompanying text.
[FN38]. Janosky et al., supra note 6, at 81.
[FN39]. Federal Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040 (codified as
amended at 21 U.S.C. §§ 301-399 (2006)) (“FDCA”). The FDCA has been amended more than 100 times.
Peter Barton Hutt, A Historical Introduction, 45 Food Drug Cosm. L.J. 17 (1990), as reprinted in Peter
Barton Hutt et al., Food and Drug Law 4 (3d ed. 2007). The Agency we now know as the FDA was created
by the Federal Food and Drugs Act of 1906. Federal Food and Drugs Act of 1906, Pub. L. No. 59-384, 34
Stat. 768 (repealed 1938); John P. Swann, About FDA: FDA's Origins, U.S. Food & Drug Admin.,
http://www.fda.gov/AboutFDA/WhatWeDo/History/default.htm (last visited Dec. 29, 2011). The Act
prohibited adulterated and misbranded food and drugs and introduced an administrative enforcement
clause to enable implementation. Paul Hyman, U.S. Food and Drug Law and FDA--A Historical
Background, in A Practical Guide to Food and Drug Law and Regulation 21 (Kenneth R. Piña & Wayne L.
Pines eds., 1st ed. 1998).
[FN40]. Richard A. Merrill, The Architecture of Government Regulation of Medical Products, 82 Va. L.
Rev. 1753 (1996), as reprinted in Hutt et al., supra note 39, at 5.
[FN41]. Hutt et al., supra note 39, at viii.

[FN43]. Id. at 624; Janosky et al., supra note 6, at 81-82; Carey, supra note 6, at 77.
[FN44]. See generally ICH Guidance Examines, supra note 28; International Conference on
Harmonisation; Guidance on Statistical Principles for Clinical Trials, 63 Fed. Reg. 49,583, 49,584 (Sept.
16, 1998). The ICH has developed shared scientific standards for clinical data and good clinical practice.
Michael J. Malinowski, Ethics in a Global Biopharmaceutical Environment, 5 Santa Clara J. Int'l L. 57, 7071 (2006), http:// www.scujil.org/sites/default/files/volumes/v5_MalinowskiArticle.pdf. For information
about the ICH, visit its official website, http://www.ich.org (last visited Dec. 29, 2011). Six conferences
have been held to date, and a seventh (the “ICH7 Conference”) was scheduled to take place March 2930, 2006, in Vienna, Austria, but was cancelled. ICH Steering Committee Meeting Summary 7 (June 5-8,
2006), available at http://www.ich.org/uploads/media/SC_Report_ Yokohama_2006.pdf. The
organization itself, with representatives from both government and industry, operates in an ongoing
manner. For an international extension of this Article that directly addresses the ICH, see Michael J.
Malinowski & Grant G. Gautreaux, All that is Gold Does Not Glitter in Human Clinical Research: A LawPolicy Proposal to Brighten the Global “Gold Standard” for Drug Research and Development, 45 Cornell
J. Int'l Law (forthcoming 2012).
[FN45]. Vision, ICH, http://www.ich.org/about/vision.html (last visited Dec. 29, 2011).
[FN46]. See International Conference on Harmonisation; Guidance on E15 Pharmacogenomics
Definitions and Sample Coding, 73 Fed. Reg. 19,074 (Apr. 8, 2008).
[FN47]. Id. at 19,075. Pharmacogenomics and pharmacogenetics are defined and discussed infra at
notes 48, 135, and 238 and accompanying text. In simplest terms, genomics is the science of genetic
expression and its influence on human health. Genomics and Health, Ctrs. for Disease Control &
Prevention, http://www.cdc.gov/genomics/public/index.htm (last updated Apr. 26, 2010). The discipline
has become prevalent at the forefront of drug development, with completion of the map of the human
genome announced in 2003. See supra note 13 and accompanying text. A biomarker is “[a] biochemical
feature or facet that can be used to measure the progress of disease or the effects of treatment.”
Definition of Biomarker, MedicineNet, http:// www.medterms.com/script/main/art.asp?articlekey=6685
(last reviewed Apr. 27, 2011). The FDA provides a table of genomic biomarkers used in approved drug
labels at Table of Pharmacogenomic Biomarkers in Drug Labels, U.S. Food & Drug Admin., http://
www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (last visited
Dec. 29, 2011).
[FN48]. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions
and Sample Coding, 73 Fed. Reg. at 19,075.
[FN49]. Ctr. for Drug Evaluation and Research, U.S. Food & Drug Admin., Guidance for Industry: E16
Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of
Qualification Submissions 1 & n.1, 2 (2011).

[FN50]. See infra notes 51-64 and accompanying text. Deviations from the standard drug approval
clinical trial process described are granted for unusual circumstances, such as trials on drug candidates
for very small patient disease groups and those for highly innovative therapeutics for presently
untreatable conditions that will expose study participants to extremely high levels of risk. The FDA's
Drug Review Process: Ensuring Drugs Are Safe and Effective, U.S. Food & Drug Admin., http://
www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm (last visited Dec. 29, 2011); see infra
notes 268-69 and accompanying text; see also Risk and Responsibility: The Roles of FDA and
Pharmaceutical Companies in Ensuring the Safety of Approved Drugs, Like Vioxx: Hearing Before the H.
Comm. on Gov't Reform, 109th Cong. 24-25 (2005) (statement of Steven Galson, Acting Director Center
for Drug Evaluation and Research) (outlining the pre-market approval process).
[FN51]. See 21 C.F.R. § 312.21(a) (2011).
[FN52]. Hutt et al., supra note 39, at 630-31.
[FN53]. 21 C.F.R. § 312.21(a).
[FN54]. Id. With an increase of innovative new drug candidates, Phase I trials have been modified in
recent years to occasionally include efficacy testing in terminally ill patients particularly where there are
nonexistent or insufficient existing treatments, thereby comingling traditional Phases I and II and clinical
research and care. See Jamie L. Aldes, Note, The FDA Clinical Trial Process: Effectuating Chance in the
Regulatory Framework Governing Clinical Trials to Account for the Historical Shift from “Traditional” to
“New” Phase I Trials, 18 Health Matrix 463, 473-74 (2008).
[FN55]. Aldes, supra note 54, at 471.
[FN56]. 21 C.F.R. § 312.21(b) (2011).
[FN57]. Id. at § 312.21(c). Stuart R. Cohn & Erin M. Swick, The Sitting Ducks of Securities Class Action
Litigation: Bio-Pharmas and the Need for Improved Evaluations of Scientific Data, 35 Del. J. Corp. L. 911,
918 (2010); Geoffrey M. Levitt, The Drugs/Biologics Approval Process, in A Practical Guide to Food and
Drug Law and Regulation, supra note 39, at 101. As discussed infra at note 79 and in the accompanying
text, over the last five years, typical Phase III trials have expanded from 5,000 to 20,000 subjects and
their cost has doubled to surpass $100 million. Nagano, supra note 1.
[FN58]. 21 C.F.R. § 314.126(a) (2010); Aldes, supra note 54, at 468. See generally W. John Thomas, The
Vioxx Story: Would it have Ended Differently in the European Union?, 32 Am. J. L. & Med. 365 (2006)
(discussing the approval of Vioxx under the American drug approval process and contrasting the U.S.
approval process with that of the European Union).
[FN59]. See supra notes 19-22 and infra note 115-19 and accompanying text.

[FN60]. Aldes, supra note 54, at 472; see 21 C.F.R. § 314.80 (2011); Hutt et al., supra note 39, at 734-38.
[FN61]. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, § 901, 121 Stat.
823, 922-43; Evans, Seven Pillars, supra note 24, at 477; see generally Evans, Authority, supra note 24;
Malinowski & Gautreaux, supra note 44.
[FN62]. Post-marketing surveillance is sometimes referred to as “Phase V” trials. See Aldes, supra note
54, at 472 (“Phase V trials monitor the effects of the drugs as reported by physicians, survey data, and
discover new uses for the drug.”).
[FN63]. See Patient-Tailored Medicine Part Two, supra note 13, at 16-17 (discussing lack of minority
participants in clinical trials).
[FN64]. Office of Inspector Gen., U.S. Dep't of Health & Human Servs., FDA's Monitoring of
Postmarketing Study Commitments 1 (2006).
[FN65]. See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, §130, 111
Stat. 2296, 2231-32 (codified at 21 U.S.C. 356b). Section 506B of FDAMA, the provision that promotes
this presumption in favor of market approval, is codified under 21 U.S.C. § 356b. That same section
provides FDA enforcement authority for 506B studies. 21 U.S.C. § 356b(d)-(e) (2006). See also Office of
Inspector Gen., supra note 64, at 1, 2-3 (discussing 506B post-marketing studies).
[FN66]. Christopher D. Zalesky, Considering Changes to CMS's National Coverage Decision Process:
Applying Lessons Learned From FDA as a Regulator of Access to Healthcare Technology, 57 Food & Drug
L.J. 73, 86 (2002); James L. Zelenay, Jr., The Prescription Drug User Fee Act: Is a Faster Food and Drug
Administration Always a Better Food and Drug Administration?, 60 Food & Drug L.J. 261, 295 (2005)
(“PDUFA II [enacted in conjunction with FDAMA] shifted the agency's focus from one based solely on
protecting the public from unsafe and ineffective products, possibly at the cost of expediency, to one
that must balance this interest in safety with an interest in providing patients with speedy access to new
drugs.”).
[FN67]. See U.S. Gov't Accountability Office, GAO-06-402, Drug Safety: Improvement Needed in FDA's
Postmarket Decision-making and Oversight Process 18-23 (2006) (finding the FDA lacks a clear and
effective process for post-market drug safety decision making); Inst. of Med., The Future of Drug Safety:
Action Steps for Congress 1 (2006) (noting FDA's lack of clear authority to enforce compliance).
[FN68]. As explained under the ICH E9 Guidance, which incorporates FDA standards, exploratory trials
“cannot be the basis of the formal proof of efficacy, although they may contribute to the total body of
relevant evidence.” International Conference on Harmonisation; Guidance on Statistical Principles for
Clinical Trials, 63 Fed. Reg. 49,583, 49,587 (Sept. 16, 1998). The Guidance “suggests that sponsors
conducting confirmatory trials estimate the size of the effects of the investigational product and relate

the estimate to actual clinical significance. Because the hypothesis to be tested is largely based on
clinical results and because a single confirmatory trial may be used to establish efficacy, adherence to
the protocol and standard operating procedures is a must ....” ICH Guidance Examines, supra note 28.
[FN69]. Green, supra note 6, at 70-71.
[FN70]. See id. Testing against a placebo is testing against nothing, which is the extreme comparison-the greatest means to document efficacy data in patient group research. See id.
[FN71]. International Conference on Harmonisation; Guidance on Statistical Principles for Clinical Trials,
63 Fed. Reg. at 49,587. The E9 Guidance recommends using double-blinding where investigational
“treatments are prepacked with a randomization schedule, and supplied to the trial center(s) labeled
only with the subject number and the treatment period so that no one involved in the conduct of the
trial is aware of the specific treatment allocated to any particular subject.” Id. According to the
Guidance, blind breaking should only occur when the trial subject's physician deems it necessary; if blind
breaking does occur, it “should be reported and explained at the end of the trial.” Id. A trend increasing
in recent years is for study participants to use modern technology to remove their half of the doubleblind--from internet access to communication with other subjects via patient group chat rooms and
blogs that enable collective information and comparisons, to sending blood samples to independent
laboratories to discern directly whether they are getting the drug candidate. Lawrence M. Friedman et
al., Fundamentals of Clinical Trials 87 (3d ed. 1996).
[FN72]. Ethics norms for domestic U.S. research, as embodied in the Common Rule, ban denial of access
to existing treatments with instances of seriously debilitating and life-threatening conditions. See Paul
Litton & Franklin G. Miller, A Normative Justification for Distinguishing the Ethics of Clinical Research
from the Ethics of Medical Care, 33 J.L. Med. & Ethics 566, 570 (2005) (“[U]nder the seven principles for
research, it would be unethical to withhold effective treatment to such ill persons for research purposes
if withholding treatment exposes a person to grave risk.”). For the same reason, once data establishes
efficacy and safety during a trial to develop treatments for such conditions, study sponsors typically
must make the drug candidate available to all of those in its trials. Id.
[FN73]. See supra note 72 and accompanying text.
[FN74]. 21 C.F.R. § 314.510 (2010). The ICH E9 Guidance suggests that,
In choosing which clinical endpoints to test for, the guidance recommends that sponsors select primary
endpoints capable of providing the most clinically relevant and convincing evidence directly related to
the trial's main objective. Typically, there should be but one primary endpoint. Usually, efficacy should
be the primary endpoint, although safety, tolerability, or quality-of-life measurements also may serve as
the foremost endpoints to be tested, the guidance states.

ICH Guidance Examines, supra note 28. The FDA has been criticized for accepting surrogate endpoints
for accelerated, conditional market approval and then failing to enforce follow-on study requirements.
U.S. Gov't Accountability Office, GAO-09-866, New Drug Approval: FDA Needs to Enhance Its Oversight
of Drugs Approved on the Basis of Surrogate Endpoints 29 (2009). According to the GAO, the FDA has
required over 144 studies since introducing the accelerated approval program in 1992. Id. at 18. More
than a third of those are still pending and the Agency never has pulled a drug for failure to conduct longterm studies. Id. at 18, 29. The FDA does not routinely check whether companies are making progress on
required studies. Id. at 29-32.
[FN75]. See supra notes 10, 17 and accompanying text (explaining the use of averages in GD statistics).
[FN76]. This point is illustrated in a discussion of the tremendous genetic diversity associated with the
health care condition categorized as “dwarfism.” See Michael J. Malinowski, Dealing with the Realities of
Race and Ethnicity: A Bioethics-Centered Argument in Favor of Race-Based Genetics Research, 45 Hous.
L. Rev. 1415, 1451-57 (2009) (profiling the Roloff family from the television show “Little People, Big
World” as a case study).
[FN77]. Janosky et al., supra note 6, at 81-82 (footnotes omitted). The renowned Dr. Jerome Groopman
has reached the same conclusion: “Statistics cannot substitute for the human being before you;
statistics embody averages, not individuals. Numbers can only complement a physician's personal
experience with a drug or a procedure, as well as his knowledge of whether a ‘best’ therapy from a
clinical trial fits a patient's particular needs and values.” Jerome Groopman, How Doctors Think 6 (2007).
Similarly, as observed by another commentator:
The best way to go from intuition to evidence is the randomized clinical trial. Patients with a particular
condition are randomly assigned to competing treatments or, if appropriate, to a placebo. By monitoring
the patients for months or years, doctors learn the relative risks and benefits of the treatment being
studied.
But such trials take years and cost many millions of dollars. By the time the results come in, science and
medicine may have moved on, making the findings less relevant. Moreover, patients in a clinical trial
usually aren't representative of real people, who tend to have complex combinations of diseases and
medical problems. And patients often don't stick with the program.
Carey, supra note 6, at 77 (emphasis added).
[FN78]. Nagano, supra note 1.

[FN80]. Id. In addition to the speed of subject recruitment (the primary driver for expansion of
recruitment outside of the United States),
To seek bigger patient pools, most major CROs have expanded operations overseas to India, Russia,
Latin America, Eastern Europe and other emerging markets. U.S.-based CROs have a presence in more
than 70 countries.
In those countries, CROs can easily find a large number of “treatment-naïve patients” who aren't taking
other drugs and are thus the best candidates for trials.
Id.
[FN81]. Ctr. for Health & Pharm. Law & Policy, Seton Hall Law, White Paper: Conflicts of Interest in
Clinical Trial Recruitment & Enrollment: A Call for Increased Oversight 5 (2009).
[FN82]. See infra Part II.
[FN83]. See supra notes 23-25 and accompanying text.
[FN84]. Gardiner Harris, A New Federal Research Center Will Help to Develop Medicines, N.Y. Times, Jan.
23, 2011, at A1.
[FN85]. See supra note 7 and accompanying text. For detailed discussion of the SSRD methodology, see
Janosky et al., supra note 6, at 25-43.
[FN86]. Janosky et al., supra note 6, at 81; see also id. at 81-96 (discussing direct application of SSRD in
biomedicine).
[FN87]. Poling et al., supra note 3, at 119.
[FN88]. Janosky et al., supra note 6, at 82.
[FN89]. Green, supra note 6, at 74. “In a single-case experiment, each data point represents one of the
repeated direct measurements of the target behavior, as opposed to a mathematical abstract like a
group mean test score. Graphing those data provides a picture of exactly how behavior unfolds in real
time under specific conditions.” Id. at 78.
[FN90]. Id. at 74. For an overview on SSRD methodology, see Blampied Presentation, supra note 7.
[FN91]. Green, supra note 6, at 78-79.

[FN93]. Id.
[FN94]. Id.
[FN95]. Id.
[FN96]. Patient-Tailored Medicine Part One, supra note 13, at 9.
[FN97]. See Green, supra note 6, at 73. As explained by Professor Green, “[l]ike other scientists,
behavior analysts have devised research methods that are suited to their particular subject matter,
while meeting all of the general requirements of science.” Id. at 73. These requirements include careful
observation, objective measurement, controlled experiments, analysis and interpretation of data, and
repetition (replication) of experiments. Id. at 70. Because the focus is on individual behavior unfolding
over time, single-case research designs are used for most behavior analytic studies. These are true
experiments, not “case studies” or nonexperimental observational studies. Id. at 74.
[FN98]. Janosky et al., supra note 6, at 28 (citations omitted). R.A. Fisher introduced the first official
single subject clinical trial experimental paradigm in 1945. Id. at 1.
[FN99]. See supra note 33 and accompanying text.
[FN100]. See supra note 33 and accompanying text.
[FN101]. See Greer & Keohane, Real Science, supra note 30, at 37-38.
[FN102]. See R. Douglas Greer, Designing Teaching Strategies: An Applied Behavior Analysis Approach
161-163 (2002).
[FN103]. Joe Levine, The Unorthodox Behaviorist, TC Today, Spring 2007, at 24, 26-27.
[FN104]. Poling et al., supra note 3, at 119.
[FN105]. Marcia Angell, The Truth About the Drug Companies, at xv (2004).
[FN106]. See Paul Starr, The Social Transformation of American Medicine, 336-37 (1982) (detailing a
growing dependence on pharmaceuticals and medical technology following World War I).
[FN107]. See, e.g., id. at 335-36 (noting, for example, advances in antibiotics and Malaria control).
[FN108]. Jürgen Drews, Drug Discovery: A Historical Perspective, 287 Sci. 1960, 1962 (2000); Michael J.
Malinowski, Respecting, Rather than Reacting to, Race in Basic Biomedical Research: A Response to

Professors Caulfield and Mwaria, 45 Hous. L. Rev. 1489, 1492 n.16 (2009); Thomas Reiss, Drug Discovery
of the Future: The Implications of the Human Genome Project, 19 Trends Biotechnology 496, 496 (2001).
“This surprisingly low number of targets illustrates that the identification of clinically relevant and
interesting targets was the primary bottleneck of the drug discovery process.” Patient-Tailored Medicine
Part One, supra note 13, at 12.
[FN109]. Drug Discovery and Development, PhRMA, http:// www.Phrma.org/research/drug-discoverydevelopment (last visited Dec. 29, 2011).
[FN110]. See Evans, Seven Pillars, supra note 24, at 439-44 (discussing efficacy as the purpose of
randomized, controlled clinical trials).
[FN111]. Patient-Tailored Medicine Part One, supra note 13, at 11-12 (citing Press Release, Tufts Ctr. for
the Study of Drug Dev., Backgrounder: How New Drugs Move Through the Development and Approval
Process (Nov. 2001), available at http://csdd.tufts.edu/files/uploads/how_new_drugs_move.pdf); see
generally Jim Gilbert et al., Rebuilding Big Pharma's Business Model, In Vivo: Bus. & Med. Rep., Nov.
2003, at 73 (2003), available at
www.bain.com/bainweb/PDFs/cms/Marketing/rebuilding_big_pharma.pdf (outlining the traditional
methods that have led the drug industry to profit loss, including a random, all-inclusive, expensive
testing process).
[FN112]. See supra notes 19-22 and accompanying text.
[FN113]. Thomas, supra note 58, at 372; Patient-Tailored Medicine Part One, supra note 13, at 24; Harris
Meyer, Costly Stamp of Approval, L.A. Times, Jan. 18, 2010, at E3. Sponsors have been required to
demonstrate safety since 1938. Id.
[FN114]. Patient-Tailored Medicine Part One, supra note 13, at 9 (“Nonetheless, not until the second
half of the twentieth century has much attention been paid to drug safety and, even then, adverse drug
reactions were considered part of the practice of medicine.”); David Classen, Medication Safety: Moving
from Illusion to Reality, 289 JAMA 1154, 1154 (2003); Evans, Seven Pillars, supra note 24, at 449.
[FN115]. See Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341, 350 (2001); Wash. Legal Found. v.
Henney, 202 F.3d 331, 333 (D.C. Cir. 2000) (calling off-label use “commonplace”); Wash. Legal Found. v.
Friedman, 13 F. Supp. 2d 51, 56 (D.D.C. 1998), vacated in part on other grounds sub nom. Wash. Legal
Found. v. Henney, 202 F.3d 331 (D.C. Cir. 2000) (observing that “off-label use of FDA-approved drugs by
physicians is an established aspect of the modern practice of medicine”).
[FN116]. Pharm. Researchers & Mfrs. of Am., Pharmaceutical Industry Profile 26 fig.8 (2010); see Ctr. for
Health & Pharm. Law & Policy, supra note 81, at 9 (calling the cost of “nontreatment activities,”
including research, considerable and substantial).

[FN117]. Angell, supra note 105, at 11-12. The FDA has estimated that almost two percent of all
prescription drugs--thousands of medicines that include powerful active ingredients such as
antihistamines, narcotics and sedatives-- are marketed illegally without its approval. Meyer, supra note
113.
[FN118]. Meyer, supra note 113 (explaining that high prices of FDA-approved drugs leads to use of
cheaper, unapproved off-label drugs).
[FN119]. Angell, supra note 105, at 123-26 (describing how direct-to-consumer advertising both
persuades and misleads consumers).
[FN120]. See Inst. of Med., supra note 67, at 2 (suggesting black triangle indicators for new drug
approvals to flag the lack of market history); Wylie Burke & Bruce M. Psaty, Personalized Medicine in the
Era of Genomics, 298 JAMA 1682, 1682-84 (2007) (detailing the potential of experimental, genetically
personalized pharmaceutical treatment).
[FN121]. Patient-Tailored Medicine Part One, supra note 13, at 9, 16-17; see also Inst. of Med., The
Future of Drug Safety: Promoting and Protecting the Health of the Public 54 box2-5 (2007) (relating
drug-specific data on adverse effects as reported to the FDA).
To some extent, clinical medicine always has been tailored to the patient in that each physician-patient
relationship is unique, and each clinical encounter represents the physician's attempt to provide the
optimal care to the patient in the examining room, the emergency room, the hospital bed, and the
intensive care unit. Nonetheless, not until the second half of the twentieth century has much attention
been paid to drug safety and, even then, adverse drug reactions were considered part of the practice of
medicine.
Today, because adverse drug reactions cause more than two million hospitalizations and 100,000 deaths
annually in the United States, there are strong clinical, economic, and ethical imperatives to address the
manifold causes of these numbers.
Patient-Tailored Medicine Part One, supra note 13, at 9 (footnotes omitted). See also BS Shastry,
Pharmacogenetics and the Concept of Individualized Medicine, 6 Pharmacogenomics J. 16, 16 (2006).
Negative outcomes may result both from errors in prescribing and dispensing and from individuals'
adverse reactions to the drugs themselves. Petra A. Thürmann, Prescribing Errors Resulting in Adverse
Drug Events: How Can They Be Prevented?, 5 Expert Opinion on Drug Safety 489, 490 (2006). It is
entirely possible that one of the causes of adverse drug reactions is the method by which individual
patients metabolize those drugs. Kathryn A. Phillips et al., Potential Role of Pharmacogenomics in
Reducing Adverse Drug Reactions: A Systematic Review, 286 JAMA 2270, 2270 (2001).
[FN122]. Shastry, supra note 121, at 16. One 2005 report stated that approximately 40,000 people are
killed in automobile accidents every year. Miranda Hitti, Car Crashes Kill 40,000 in U.S. Every Year, Fox

News (Feb. 3, 2005), http://www.foxnews.com/story/0,2933,146212,00.html.
[FN123]. Carey, supra note 6, at 73 (reporting on the movement for evidence-based medicine).
[FN124]. See generally Starr, supra note 106.
[FN125]. See generally Genomics Revolution, supra note 13; Nagano, supra note 1 (“The consensus on
Wall Street: Big Pharma's business model is ‘broken, and no longer working’....”).
[FN126]. See Press Release, U.S. Food & Drug Admin., FDA Completes Final Phase of Planning for
Consolidation of Certain Products from CBER to CDER, (Mar. 17, 2003), available at http://
www.scienceblog.com/community/older/archives/M/2/fda1387.htm. Until 2004, biologic drugs were
reviewed by the Center for Biologics Evaluation and Research. Transfer of Therapeutic Products to the
Center for Drug Evaluation and Research, U.S. Food & Drug Admin., http://
www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm133463.htm
(last visited Dec. 29, 2011). Where the drugs were a combination of traditional and biotech, sponsors
had some choice in where to file for review. Influenced by the trend of biopharmaceuticals, all drug
review and the relevant resources were centralized in CDER. Id.
[FN127]. See Transfer of Therapeutic Products, supra note 126.
[FN128]. See Press Release, Nat'l Human Genome Research Inst., International Consortium Completes
Human Genome Project, (Apr. 14, 2003), available at http://www.genome.gov/11006929 [hereinafter
International Consortium]. The Human Genome Project (“HGP”), commenced in 1990, was undertaken
to identify and map the sequence of information coded in DNA and to identify active human genes-segments of DNA. Id.; Patient-Tailored Medicine Part One, supra note 13, at 10-11. A rough map of the
human genome was completed in 2003, years ahead of schedule. Patient-Tailored Medicine Part One,
supra note 13, at 11. Information about the HGP may be obtained from the National Human Genome
Research Institute (“NHGRI”) at www.nhgri.nih.gov/HGP. For more information on the human genome
generally, see the February 16, 2001 issue of Science entitled “The Human Genome,” 291 Sci. 1145
(2001) and the February 15, 2001 Issue of Nature, 409 Nature 745 (2001), also entitled “The Human
Genome” dedicated to a draft of the map of the human genome. See also Subcomm. on Human
Genome of the Health & Envtl. Research Advisory Comm. for the U.S. Dep't of Energy, Report on the
Human Genome Initiative for the Office of Environmental Research (1987), available at
www.ornl.gov/sci/techresources/Human_ Genome/project/herac2.shtml (discussing the need for and
value of a map of human DNA); Eric S. Lander, Scientific Commentary: The Scientific Foundations and
Medical and Social Prospects of the Human Genome Project, 26 J.L. Med. & Ethics 184, 184 (1998)
(explaining the HGP and the possibilities that arise with unlocking the “human periodic table”). Once
genes are identified, comparisons can be made among individuals to identify genetic variations and
assess their function and impact on human health. See Ctr. for Genetics Educ., The Human Genetic
Code--The Human Genome Project and Beyond (2007), available at
www.genetics.com.au/pdf/factsheets/fs24.pdf (noting diagnosis and predictive testing for genetic

conditions).
[FN129]. See Press Release, Nat'l Human Genome Research Inst., International Consortium Announces
the 1000 Genomes Project (Jan. 22, 2008), available at
http://www.1000genomes.org/sites/1000genomes.org/files/docs/1000genomes-newsrelease.pdf.
An international research consortium today announced the 1000 Genomes Project, an ambitious effort
that will involve sequencing the genomes of at least a thousand people from around the world to create
the most detailed and medically useful picture to date of human genetic variation. The project will
receive major support from the Wellcome Trust Sanger Institute in Hinxton, England, the Beijing
Genomics Institute, Shenzhen (BGI Shenzhen) in China and the National Human Genome Research
Institute (NHGRI), part of the National Institutes of Health (NIH).
Id.
[FN130]. Peter Imming et al., Drugs, Their Targets and the Nature and Number of Drug Targets, 5 Nature
Reviews: Drug Discovery 821, 830 (2006). A drug target is “a molecular structure (chemically definable
by at least a molecular mass) that will undergo a specific interaction with chemicals that we call drugs
because they are administered to treat or diagnose a disease. The interaction has a connection with the
clinical effect(s).” Id. at 821.
[FN131]. See supra note 13 for a discussion of epigenetics.
[FN132]. See Biotechnology Indus. Org., Guide to Biotechnology 2008 32-40 (2008), available at
http://www.bio.org/node/2801 (discussing some of the therapies made possible by recent research
advances).
[FN133]. Patient-Tailored Medicine Part One, supra note 13, at 11.
[FN134]. William E. Evans & Mary V. Relling, Moving Towards Individualized Medicine With
Pharmacogenics, 429 Nature 464, 466, 468 (2004). More than 3 million human genetic variations, called
single nucleotide polymorphisms (“SNPS”), had been identified by April 2003. International Consortium,
supra note 128.
[FN135]. In simplest terms, pharmacogenomics utilizes genetic profiling in pharmacology--for example,
centering a human clinical trial on members of a disease group under study who share a particular
genetic variation. When successful, the result is associations between specific human genetic variations
and responsiveness to pharmaceuticals, thereby enabling individualized medicine based on genetic
profiling, which is a field known as pharmacogenetics. See supra notes 46-47 and accompanying text.
Complementary fields are pharmacogenomics, which is research centered on the expression of alleles
shared by groups, and pharmacogenetics, the tailoring of health care and biopharmaceuticals to
individual genetic profiles. See Malinowski, supra note 13, at 32; Noah, supra note 13, 7-11; Janet

Woodcock, FDA Policy on Pharmacogenomic Data in Drug Development, 66 La. L. Rev. 91, 92 (2005).
[FN136]. See Patient-Tailored Medicine Part One, supra note 13, at 6-7; Burke & Psaty, supra note 120,
at 1684; Susan B. Shurin & Elizabeth G. Nabel, Pharmacogenomics--Ready for Prime Time?, 358 New
Eng. J. Med. 1061, 1062-63 (2008). “Biotechnology also has created a wave of new genetic tests. Today
there are more than 1,200 such tests in clinical use, according to genetests.org, a site sponsored by the
University of Washington. Many are for genetic diseases, while others test predisposition to disease.
Emerging applications include tests to predict response to medicines and assist with nutritional
planning.” Biotechnology Indus. Org., supra note 132, at 32.
[FN137]. Patient-Tailored Medicine Part One, supra note 13, at 12. See also The Int'l SNP Map Working
Grp., A Map of Human Genome Sequence Variation Containing 1.42 Million Single Nucleotide
Polymorphisms, 409 Nature 928, 932 (2001) (discussing the various benefits anticipated from the human
genome map).
[FN138]. See generally Robert Bazell, Her-2: The Making of Herceptin, a Revolutionary Treatment for
Breast Cancer (1998).
[FN139]. Brian J. Druker, STI571 (Gleevec™) as a Paradigm for Cancer Therapy, 8 Trends Molecular Med.
S14, S14 (2002).
[FN140]. Steven Reinberg, New Cancer Drug Fights Tumors in Those with BRCA Mutations, U.S. News &
World Rep. (June 24, 2009), http:// health.usnews.com/articles/health/healthday/2009/06/24/newcancer-drug-fights-tumors-in-those-with-brca.html.
[FN141]. See Angell, supra note 105, at xv-xvii; U.S. Food & Drug Admin., Innovation or Stagnation:
Challenge and Opportunity on the Critical Path to New Medical Products (2004), available at http://
www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunities
Reports/ ucm113411.pdf (providing a comprehensive discussion on the challenges facing
biopharmaceuticals, despite recent advances in biomedical research, as well as potential solutions);
Bitter Medicine: Pills, Profit, and the Public Health (ABC News television broadcast May 29, 2002).
[FN142]. Nicholas Wade, A Decade Later, Gene Map Yields Few New Cures, N.Y. Times, June 13, 2010, at
A1.
[FN143]. See Patient-Tailored Medicine Part One, supra note 13, at 35.
[FN144]. See supra notes 1-3 and accompanying text.
[FN145]. Pharm. Researchers & Mfrs. of Am., supra note 116, at iii.
[FN146]. Jared A. Favole & Jennifer Corbett Dooren, FDA Approved More Drugs in 2008, Wall St. J., Jan.

2, 2009, at A9; New Drug Approvals on Pace to Exceed 2008 Total, supra note 1; Silverman, supra note 1;
see also Jenna Greene, Has Obama Redirected the Regulatory System?, Nat'l L. J., Jan. 18, 2010, at 11
(noting that the number of FDA approvals under the Obama administration are “on par or even more
accommodating than” the Bush Administration); Pete Harpum, Articulating a Vision for Best Practice
Project Management in Drug Development, PM World Today, Oct. 2008, at 1, http://
www.pmforum.org/library/papers/2008/PDFs/Harpum-10-08.pdf.
[FN147]. See Asher Mullard, 2010 FDA Drug Approvals, 10 Nature Revs.: Drug Discovery 82, 84 tbl.1
(2011) (listing CDER's approvals in 2010 in chart form).
[FN148]. FDA's Drug Approvals Flat 2009, Safety Up, MSNBC (Jan. 5, 2010, 1:37 PM),
http://www.msnbc.msn.com/id/34708085/ns/health-health_care/t/fdas-drug-approvals-flat-safety/.
[FN149]. Harris, supra note 2.
[FN150]. Id.
[FN151]. Id.
[FN152]. Ctr. for Health & Pharm. Law & Policy, supra note 81, at 6.
[FN153]. Nagano, supra note 1.
[FN154]. Ctr. for Health & Pharm. Law & Policy, supra note 81, at 5.
[FN155]. Nagano, supra note 1.
[FN156]. See U.S. Gov't Accountability Office, supra note 67; Inst. of Med., supra note 67.
[FN157]. Thomas, supra note 58, at 371-73.
[FN158]. Gina Kolata, When Drugs Cause Problems They Are Supposed to Prevent, N.Y. Times, Oct. 17,
2010, at A18.
[FN159]. Id.
[FN160]. Id. The recent Avandia controversy triggered an expansive U.S. Senate Finance Committee
inquiry and bipartisan report highly critical of both GlaxoSmithKline (“GSK”) and the FDA. See Staff of S.
Comm. on Finance, 111th Cong., Rep. on GlaxoSmithKline and the Diabetes Drug Avandia 1 (Comm.
Print. 2010) [hereinafter Report on Avandia]. This medication, introduced to the market in 1999 and
prescribed to hundreds of thousands of patients annually to treat type 2 diabetes, caused 83,000 heart
attacks between 1999 and 2007, according to the FDA's own estimates. Id. at 1-4; Gardiner Harris,

Research Ties Diabetes Drug to Heart Woes, N.Y. Times, Feb. 20, 2010, at A1. GSK researchers identified
a link between Avandia and serious heart disease in 2004, 2005, and 2006, the FDA issued a warning in
2007, the FDA's top officials in the Office of Surveillance and Epidemiology recommended a full market
recall, and internal FDA reports indicated that switching Avandia patients to an alternative drug could
prevent about 500 heart attacks and 300 cases of heart failure each month. Report on Avandia, supra, at
14, 93; Harris, supra. According to the Senate Report, executives at the pharmaceutical company
“attempted to intimidate independent physicians, focused on strategies to minimize or misrepresent
findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that a
competing drug might reduce cardiovascular risk.” Report on Avandia, supra, at 1. GSK responded by
challenging the report and defending Avandia. Id. at 8. Although GSK is undertaking another round of
clinical trials to research the increased risk of heart disease, those are not projected to be completed
until 2020. Harris, supra. Many lawmakers, consumer advocates, and other stakeholders are calling for
regulatory reform of the FDA to grant officials in the Office of Surveillance and Epidemiology
independent decision-making power on par with that of officials who approve drugs. Alyah Khan, Recent
Avandia Report Sparks Concerns Over Internal FDA Power Struggle, FDA Wk., Feb. 26, 2010, at 4, 4. This
suggestion was made years earlier, including in the 2006 Institute of Medicine's Report on the FDA and
in the law literature. Inst. of Med., supra note 67, at 1, 3; see Thomas, supra note 58, at 379.
[FN161]. Kolata, supra note 158.
[FN162]. Steven Bushong, Accutane Off Shelves, but Lawsuits Live, Columbus Dispatch, July 3, 2009, at
A1; Accutane Side Effects, Drug Watch, http:// www.drugwatch.com/accutane/side-effects.php (last
modified Sept. 30, 2011).
[FN163]. Accutane Side Effects, supra note 162; Press Release, Roche Pharmaceuticals, Roche
Discontinues and Plans to Delist Accutane in the U.S. (June 29, 2009), available at http://
www.rocheusa.com/portal/synergy/static/file/synergy/alfproxy/download/1414cd2ddc12b4d211deadd62f6357bc6b3c/last/roche%20discontinues%C20and%C20plans%C20to%C20deli
st%C20accutane%C20in%C20the%ü.s..pdf.
[FN164]. For a thoughtful argument of over-regulation, see Richard A. Epstein, Overdose: How Excessive
Government Regulation Stifles Pharmaceutical Innovation (2006). Note, however, that Professor Epstein
does not directly address or challenge the core proposal of this Article--changing the core science
standard in the context of the existing regulatory infrastructure.
[FN165]. See Angell, supra note 105, at 7-10, 13-17.
The culture within the FDA, [is] one where the pharmaceutical industry, which the FDA is supposed to
regulate, is seen by the FDA as its client instead.” The lack of adequate regulation of the pharmaceutical
industry by the FDA has led to many deaths and recalls of unsafe drugs, such as Vioxx, that the FDA had
approved for public use [in 1999]. As Sen. Charles Grassley (R-Iowa) explained, “[c]onsumers should not
have to second-guess the safety of what's in their medicine cabinet.” Unfortunately, many consumers

suffer as a result of the current ineffective state of the FDA's regulatory framework governing the drug
testing and approval process.
Aldes, supra note 54, at 463 (footnotes omitted).
[FN166]. For an excellent treatment of the Vioxx controversy with a focus on the overall U.S. and EU
regulatory processes for pharmaceuticals, see Thomas, supra note 58. Vioxx illustrates all too vividly
that, without meaningful regulatory reform, it may take many years of market use; tremendous financial
costs to consumers, taxpayers, and other payers; lost opportunities to improve human health; and even
the loss of many human lives before serious product shortcomings are confronted. In a 2002 broadcast
journalism documentary entitled Bitter Medicine: Pills, Profit, and the Public Health, supra note 141,
Vioxx was challenged on many levels--several years before its market recall. Nevertheless, the product
remained on the market at tremendous cost above over-the-counter alternatives such as Ibuprofen,
only to be exposed and pulled from the market in 2004. Thomas, supra note 58, at 366, 368.
[FN167]. Nagano, supra note 1. CROs are commercial service providers that meet both basic and clinical
research needs, and the business is burgeoning. Id. Unfortunately, guidance and enforceable law-policy
to protect human subjects has not been introduced in sync with this trend:
The globalization of medical research is, in effect, quickly outpacing the development of internationally
accepted ethical guidelines for the conduct of research. For many medical researchers working in
resource-poor countries, ethical decision-making is like sailing in the days before modern navigation;
one is never quite sure where one is, or in what direction one is headed.
Daniel W. Fitzgerald & Angela Wasunna, Away from Exploitation and Towards Engagement: An Ethical
Compass for Medical Researchers Working in Resource-Poor Countries, 33 J.L. Med. & Ethics 559, 559
(2005); see also Malinowski, supra note 44, at 70-71 (offering several options for dealing with the gap);
Jennifer L. Gold & David M. Studdert, Clinical Trials Registries: A Reform That Is Past Due, 33 J.L. Med. &
Ethics 811, 811 (2005) (supporting the establishment of a conclusive registry for clinical trials conducted
abroad); Joe Stephens, Where Profits and Lives Hang in Balance, Wash. Post, Dec. 17, 2000, at A1
(discussing the lack of regulation and oversight characteristic of trials in some foreign countries).
A sign of the trend: In August, Princeton, N.J.-based CovanceCVD, the largest U.S. CRO, struck a deal
with Eli Lilly to buy Lilly's R&D labs in Indiana for $50 million. The deal will transfer 260 Lilly employees
to Covance. Lilly also guaranteed Covance a 10-year business contract worth $1.6 billion.
Nagano, supra note 1.
[FN168]. Both the GAO and IOM have criticized the FDA's performance regulating new drugs in the
marketplace and emphasized the need to make the clinical research data submitted for market approval
transparent to the public. U.S. Gov't Accountability Office, supra note 67, at 5; Inst. of Med., supra note
67, at 3. Neither Congress nor the FDA have addressed the possibility that the drop-off in innovative

new drug approvals and poor performance of many on the market are an indication that the integrity of
the entire forthcoming generation of biopharmaceuticals has been jeopardized by law and policy that
comprehensively integrated academia and industry without shoring up the public nature of science.
Michael J. Malinowski, Keynote Address: A Discourse on the Public Nature of Research in Contemporary
Life Science: A Law-Policy Proposal to Promote the Public Nature of Science in an Era of AcademiaIndustry Integration, in Biennial Review of Law, Science & Technology 1, 9-12 (2010). During the span of
the career of a single academic researcher, norms have shifted from industry independence, collegiality,
disclosure and sharing of materials and information, quick and unfettered publication, and broad
dissemination of information that invited meaningful scrutiny and rigorous peer review to strong
technology transfer administration within academic research institutions, no communication without
executed confidentiality and disclosure agreements and provisional patent applications, no publication
without sponsor preapproval, and no sharing of materials without executed material transfer
agreements. See id. at 9-19.
[FN169]. Press Release, U.S. Food & Drug Admin., FDA Forms Transparency Task Force (June 2, 2009),
available at http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm163899.htm. In
2004, Congress considered measures to force public disclosure of clinical data through the Internet to
enable scrutiny by the medical and science communities, but then backed away when some of the major
pharmaceutical companies announced they would do so voluntarily. See Ted Agres, Congress Wants
Data to Be Free, Drug Discovery & Dev., Nov. 2004, at 14; Editorial, Hiding the Data on Drug Trials, N.Y.
Times, June 1, 2005, at A20 (commenting on a government survey that “determined that three of the
largest drug companies [Merck, GlaxoSmithKline, and Pfizer] have effectively reneged on their pledges
to list trials in a federal database”); Tamsin Waghorn, Rattled Drug Giants Act Over Safety Concerns,
Express, Jan. 7, 2005, at 78.
[FN170]. See Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 130, 111
Stat. 2296, 2231-32 (codified at 21 U.S.C. 356b; 21 U.S.C. § 355a (2006)). The Agency's mission was
expanded from ensuring efficacy and safety to including efficiency. See supra note 66 and accompanying
text.
[FN171]. Prescription Drug User Fee Act of 1992, Pub. L. No. 102-571, 106 Stat. 4491 (codified primarily
at 21 U.S.C. § 379g-h). PDUFA, which was enacted with a five year sunset provision, has been
reauthorized three times. See supra note 66 (PDUFA II enacted in conjunction with FDAMA in 1997);
Public Health Security and Bioterrorism Preparedness and Response Act of 2002, Pub. L. No. 107-188, §§
501-509, 116 Stat. 594, 687-694 (PDUFA III); Food and Drug Administration Amendments Act of 2007,
Pub. L. No. 110-85, §§ 101-109, 121 Stat. 823, 825-842 (codified as amended in scattered sections of 21
U.S.C.) (authorizing PDUFA IV through 2012).
[FN172]. Food and Drug Administration Modernization Act of 1997, 111 Stat. 2296.
[FN173]. Evans, Seven Pillars, supra note 24, at 454 n.240, 478, 486.

[FN174]. U.S. Gov't Accountability Office, supra note 74, at 15. For a critique of the FDA's post-market
decision-making process, see U.S. Gov't Accountability Office, supra note 67.
[FN175]. U.S. Gov't Accountability Office, supra note 74, at 32-33.
[FN176]. Id. at 33. For example, Shire Laboratories failed to complete a study for ProAmatine, a
medication for low blood pressure, for more than thirteen years. Id. at 33-34.
[FN177]. U.S. Gov't Accountability Office, supra note 67, at 18-36; Inst. of Med., supra note 67, at 1.
[FN178]. Malinowski, supra note 168, at 23.
[FN179]. Id. at 13-19.
[FN180]. Lorelei Ritchie de Larena, The Price of Progress: Are Universities Adding to the Cost?, 43 Hous.
L. Rev. 1373, 1375 (2007). For another evaluation of the Bayh-Dole Act, which gave universities greater
patent rights, see David C. Mowery et al., Ivory Tower and Industrial Innovation: University-Industry
Technology Transfer Before and After the Bayh-Dole Act (2004).
[FN181]. Malinowski, supra note 168, at 16. Several of the most renowned science publications,
including the New England Journal of Medicine and Journal of the American Medical Association
(“JAMA”), have been involved in embarrassing conflicts of interest controversies. See Linda A. Johnson,
New England Journal of Medicine Admits Lapses in Ethics Policy, Chi. Sun-Times, Feb. 24, 2000, at 21
(reporting that the “New England Journal of Medicine admitted violating its financial conflict-of-interest
policy 19 times over the last three years in its selection of doctors to review new drug treatments”).
The primary guidance for conflict of interest management by medical journals is the Uniform
Requirements for Manuscripts Submitted to Biomedical Journals, a consensus document issued and
subsequently revised by the International Committee of Medical Journal Editors (ICMJE) and allegedly
utilized by more than 500 journals. See International Committee of Medical Journal Editors, Uniform
Requirements for Manuscripts Submitted to Biomedical Journals, 277 JAMA 927, 927 (1997).... Despite
widespread utilization of the ICMJE requirements, according to a report published in the April 2001 issue
of Science and Engineering Ethics by Sheldon Krimsky and co-authors from the University of California at
Los Angeles, “[i]n reviewing 61,134 scholarly articles published in 181 academic journals in 1997,
researchers ... found that just one-half of 1 percent detailed personal financial interests, including
consulting arrangements, honorariums, expert witness fees, company equity and stock, and patents.”
Sheryl Gay Stolberg, Scientists Often Mum About Ties To Industry, N. Y. Times, Apr. 25, 2001, at A17.
Moreover, those disclosures all appeared in just one-third of the 181 journals. Id.
Michael J. Malinowski, Institutional Conflicts and Responsibilities in an Age of Academic-Industry
Alliances, 8 Widener L. Symp. J. 47, 59 n.57 (2001).

[FN182]. See Thomas, supra note 58, at 376.
[FN183]. The PDUFA legislation and user fee system are addressed supra notes 170-74 and
accompanying text.
[FN184]. Commentators have estimated that there are as many as six lobbyists working in Washington,
D.C. on behalf of the pharmaceutical sector for every member of Congress. Sharyl Attkisson, Health Care
Lobbyists' Rise to Power, CBS News (Oct. 29, 2009),
http://www.cbsnews.com/stories/2009/10/20/cbsnews_ investigates/main5403220.shtml; see also
20/20: Sick in America: Whose Body is it Anyway? (ABC News television broadcast Sept. 14, 2007).
[FN185]. Angell, supra note 105, at 118-21; See Thomas, supra note 58, at 366.
[FN186]. See U.S. Food & Drug Admin., supra note 141, at i.
[FN187]. See supra note 184 and accompanying text (noting the industry's lobbying resources).
[FN188]. See supra note 171 for a discussion of PDUFA I-IV.
[FN189]. See Biotechnology Indus. Org., supra note 132, at 38; BioBytes: The Biotech Drug Delivery
Timeline, Biotechnology Indus. Org., http:// www.bio.org/content/biobytes-biotech-drug-deliverytimeline (last visited Dec. 29, 2011) (providing a short video discussing the drug development process);
Drug Discovery Timeline, PhRMA, http://www.phrma.org/media/multimedia/drug-discovery-timeline
(last visited Dec. 29, 2011) (same).
[FN190]. Consider that when former President Clinton and former Prime Minister Tony Blair made a
statement on March 14, 2000, that was critical of biotechnology patenting, the sector dropped by $100
billion over the next 24 hours. Malinowski, supra note 13, at 60 n.167.
[FN191]. See supra notes 124-125, 134 and accompanying text.
[FN192]. See generally Genomics Revolution, supra note 13 (discussing the advantages of genomics,
including protein expression).
[FN193]. Patient-Tailored Medicine Part One, supra note 13, at 35 (assessing that the advent of
personalized medicine is at least a decade in the future); Patient-Tailored Medicine Part Two, supra note
13, at 42.
[FN194]. Woodcock, supra note 135, at 93. Sophisticated genetic screening capabilities exist, but that is
not the equivalent of them being commercially available. See Malinowski, supra note 13, at 56-58. For
example, in April 2010 scientists announced a screening technique that can predict approximately three

quarters of smokers who will develop lethal lung cancers. Joseph Hall, Smokers' Odds Just Got a Lot
Better, Toronto Star, Apr. 8, 2010, at A1. Science researchers also have developed a test that measures
the expression of twenty-one genes to quantify the risk of breast cancer recurrence and make better
treatment decisions. Biotechnology Indus. Org., supra note 132, at 35. The National Institutes of Health
is advancing testing in oncology through The Cancer Genome Atlas, a project to map gene variations
that cause cancer, spur its growth, and cause therapeutic resistance. Id.
[FN195]. See Biotechnology Indus. Org., supra note 132, at 2. See also supra note 141 and accompanying
text. Visit the official sites of the industry's trade organizations: the Biotechnology Industry Organization
(“BIO”) at www.bio.org, and the Pharmaceutical Research and Manufacturers of America (“PhRMA”) at
www.PhRMA.org.
[FN196]. See supra notes 115-20 and accompanying text (describing the rise in off-label prescribing).
Protections for human subjects are afforded under the Common Rule triggered by federal funding of
research and FDA regulations imposed as a condition to engage in research under its watch--to which
off-label use of drugs does not apply. See 45 C.F.R. § 46.122 (2010); 21 C.F.R. § 50.1 (2010).
[FN197]. Cf. John F. Niblack, Toward a Structured National Program to Speed the Invention and
Development of New Technologies for Measuring the Progression of Chronic Diseases, in Biomarkers
and Surrogate Endpoints: Clinical Research and Applications, at xviii-xxi (Gregory J. Downing ed., 2000)
(describing the role of genomic technology in preventing and treating chronic disease); Robert H.
Glassman & Anthony Y. Sun, Biotechnology: Identifying Advances from the Hype, 3 Nature Reviews:
Drug Discovery 177 (2004) (considering the causes of slow developments in biotechnology and ways to
increase biotechnology value capture); David F. Horrobin, Modern Biomedical Research: An Internally
Self-Consistent Universe with Little Contact with Medical Reality?, 2 Nature Reviews: Drug Discovery 151
(2003) (calling for a critical assessment of the use of in vitro and animal models to understand human
disease). As observed by the FDA,
Greater success along the critical path demands greater activity in a specific type of scientific research
that is directed at modernizing the product development process. Such research--highly pragmatic and
targeted in its focus on issues such as standards, methods, clinical trial designs and biomarkers--is
complementary to, and draws extensively from, advances in the underlying basic sciences and new
technologies. Without a concerted effort to improve the critical path, it is likely that many important
opportunities will be missed and frustration with the slow pace and poor yield of traditional
development pathways will continue to escalate.
U.S. Food & Drug Admin., supra note 141, at 29. As stated by a proponent of applying SSRD in drug
development research:
Research in biomedicine appears to rely on randomized parallel group clinical trial designs and considers
these trials the “gold standard” when determining treatment effectiveness. However, large-scale trials
contain inherent limitations in that they can be expensive and time consuming. In addition, patients are
unique and may not respond similarly to various treatments, and in those instances a randomized

clinical trial design may be inappropriate. Guidelines are established from the averaged study findings,
which may not necessarily be applicable when evaluating suitable treatment options for individuals.
Specifically, patients treated in primary care settings may differ clinically from patients in the clinical
trial, the patient diversity in the clinical trial may not generalize to certain patient populations, and the
stringent trial criteria for accepting participants may not accurately reflect general patient populations.
This is an important consideration as the field of biomedicine strives to pursue cultural competency.
Janosky et al., supra note 6, at 81-82 (footnotes omitted).
[FN198]. Janosky et al., supra note 6, at 25.
[FN199]. See supra Part II (addressing drug underdevelopment, including the limited number of drug
targets used to treat all human ailments); infra Part III.C (describing the absence of regulatory oversight
of drugs in light of the current dependence on the medical community on off-label drug
experimentation).
[FN200]. See Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823
(codified as amended in scattered sections of 21 U.S.C.) (authorizing fees that will go toward expediting
drug development and increasing post-market drug safety); U.S. Food & Drug Admin., supra note 141, at
11.
[FN201]. Patient-Tailored Medicine Part One, supra note 13, at 28.
[FN202]. Janosky et al., supra note 6, at 81; see also Burke & Psaty, supra note 120, at 1684 (noting the
individualized nature of clinical health care); Patient-Tailored Medicine Part One, supra note 13, at 9
(same).
[FN203]. See supra Part I.B.
[FN204]. Janosky et al., supra note 6, at 81.
[FN205]. Id. at 82, 95 (“Single subject designs also provide greater flexibility for treatments, as
ineffective interventions can be modified over the period of study. Thus, single subject designs should
be considered when conducting research in biomedicine, as the methodology and interventions can be
tailored for specific individuals.” (footnotes omitted)).
[FN206]. For a thoughtful treatment of products liability in the context of pharmaceuticals, see PatientTailored Medicine Part Two, supra note 13, at 21-36.
[FN207]. See supra notes 78-84 and accompanying text.

[FN208]. Janosky et al., supra note 6, at 27-28.
[FN209]. Id. at 28.
[FN210]. Id. For further discussion of financial conflicts of interest in the research setting, see Ctr. for
Health & Pharm. Law & Policy, supra note 81.
[FN211]. While innovative new drug returns on the HGP have been disappointing thus far, genomics has
introduced a new dimension of research opportunity and is impacting clinical medicine. See Robert
Goldberg & Peter Pitts, Prescription for Progress: The Critical Path to Drug Development 1, 7-9 (21st
Century FDA Task Force Working Paper, 2006), available at http:// www.manhattaninstitute.org/pdf/CMP_FDA_Task_Force.pdf; Patient-Tailored Medicine Part One, supra note 13, at 8-9.
[FN212]. See Patient-Tailored Medicine Part One, supra note 13, at 7, 16-17.
[FN213]. Personalized Med. Coal., The Case for Personalized Medicine 4 (2006), available at http://
www.cspo.org/outreach/md/docs/TheCaseforPersonalizedMedicine.pdf; Patient-Tailored Medicine Part
One, supra note 13, at 16-17.
[FN214]. Lyle J. Palmer et al., Pharmacogenetics of Asthma, 165 Am. J. Respiratory & Critical Care Med.
861, 861 (2002); Alix Weisfeld, Comment, How Much Intellectual Property Protection Do the Newest
(and Coolest) Biotechnologies Get Internationally?, 6 Chi. J. Int'l L. 833, 835 (2006).
[FN215]. See supra notes 160, 168, and 200 and accompanying text.
[FN216]. Professor Janosky provides a full annotated bibliography of SSRD articles recently published in
PsycInfo, MEDLINE, and PubMed. Janosky et al., supra note 6, at 97-114.
[FN217]. See supra note 7 and accompanying text.
[FN218]. Janosky et al., supra note 6, at 83.
[FN219]. Id. at 82-84.
[FN220]. Id. at 82 (footnotes omitted).
[FN221]. Id. at 1.
[FN222]. Green, supra note 6, at 79.
[FN223]. Inst. of Med., Small Clinical Trials: Issues and Challenges 57-59 (Charles H. Evans, Jr. & Suzanne
T. Ildstad eds., 2001).

[FN224]. Id. at 16 tbl.1-2; see also Janosky et al., supra note 6, at 2 (discussing the IOM Report and
elaborating on SSRD methodology).
[FN225]. See supra notes 78-79 and accompanying text.
[FN226]. Over the last five years, Phase III trials have expanded from 3000 to 20,000 subjects and their
cost has doubled to reach $100 million. See supra note 79 and accompanying text.
[FN227]. Inst. of Med., A National Cancer Clinical Trials System for the 21st Century 29 (2010); Opinion,
Faltering Cancer Trials, N.Y. Times, Apr. 25, 2010, at A11.
[FN228]. Johnston & Pennypacker, Strategies and Tactics, supra note 7, at 304. Johnston and
Pennypacker propose that researchers “not create group data until they have already conducted a
thorough analysis of the individual data that is included.” Id.
[FN229]. Id. As explained by Johnston and Pennypacker, “One reason for this rule is that group data
obscures individual patterns of responding. Regardless of whether the collated data present an
interesting or expected picture, they do not necessarily represent what can be seen by looking at the
records from each individual subject.” Id.
[FN230]. Id. at 298.
[FN231]. Imposing SSRD as a substitute for GD is not practicable or even desirable at this time. See supra
notes 189-90 and accompanying text.
[FN232]. See supra Part I.A (discussing the phases of the clinical trial process).
[FN233]. See supra notes 228-30 and accompanying text.
[FN234]. See Inst. of Med., supra note 227, at 99 (describing a new strategy of using small “targeted trial
designs”); Janosky et al., supra note 6, at 93-95 (describing the use of SSRD for a patient study involving
a forty-two-year-old mixed race male with elevated blood pressure). “Treatments are often unavailable
for unique patient populations or rare disorders, and researchers are left uncertain what designs or
tools to use when implementing treatments.” Id. at 82.
[FN235]. Janosky et al., supra note 6, at 28-29 (footnotes omitted).
[FN236]. See id. at 82. “This methodology is also particularly suited for primary care practice-based
research, where practitioners can tailor individualized treatments to improve outcomes.” Id. at 29.

Tsapas and Matthews discussed that N-of-1 trials can be an optimal approach when treating chronic
diseases such as diabetes mellitus, which frequently rely on clinical judgment and arbitrary criteria. The
authors stated that guidelines for treating diabetes have been criticized as being unreliable, as
algorithms are generally established from “clinical judgment and experience.” Single subject designs
take into account the uniqueness of the individual, rather than using a standardized treatment that may
not be effective for all diabetics.
Id. at 83 (footnote omitted).
[FN237]. Id. at 95. For documentation of the use of SSRD in biomedicine, see Janosky et al., supra note 6,
at 97-114.
[FN238]. Patient-Tailored Medicine Part One, supra note 13, at 5.
[FN239]. See supra Part II.B.
[FN240]. Press Release, U.S. Food & Drug Admin., FDA Works to Speed the Advent of New, More
Effective Personalized Medicine (Mar. 22, 2005), available at http://
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108423.htm. As stated by the
FDA,
This guidance is intended to facilitate scientific progress in the field of pharmacogenomics and to
facilitate the use of pharmacogenomic data in drug development. The guidance provides
recommendations to sponsors holding investigational new drug applications (INDs), new drug
applications (NDAs), and biologics license applications (BLAs) on (1) when to submit pharmacogenomic
data to the Agency during the drug or biological drug product development and review processes, (2)
what format and content to provide for submissions, and (3) how and when the data will be used in
regulatory decision making.
U.S. Food & Drug Admin., Guidance for Industry: Pharmacogenomic Data Submissions 1 (2005), available
at http:// www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126957.pdf (footnote
omitted) [hereinafter U.S. Food & Drug Admin., Guidance]. For discussion of the clinical applications of
pharmacogenomics and use of it to tailor therapies, see Pharmacogenomics and Its Role in Drug Safety,
FDA Drug Safety Newsl. (U.S. Food & Drug Admin, Wash., D.C.), Winter 2008, at 24, available at http://
www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/ucm109169.pdf. The FDA and the
European Medicines Agency (“EMEA”) have promoted the voluntary submission of genomic data jointly.
U.S. Food & Drug Admin. & Eur. Meds. Agency, Guiding Principles: Processing Joint FDA EMEA Voluntary
Genomic Data Submissions within the framework of the Confidentiality Arrangement (2006), available at
http://
www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm085378.pdf;
Federico Goodsaid, U.S. Food & Drug Admin., Joint USFDA-EU Pharmacogenomic Initiatives (2006),
available at http:// www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm119097.pdf

(presentation on joint FDA-EU pharmacogenomic initiatives). To implement the guidelines and develop
related policy and standards, the FDA created the Interdisciplinary Pharmacogenomic Review Group
(“IPRG”). See Ctr. for Drug Evaluation and Research, U.S. Food & Drug Admin., Manual of Policies and
Procedures 4180.2: Management of the Interdisciplinary Pharmacogenomics Review Group (IPRG)
(2005), available at http://
www.fda.gov/downloads/AboutFDA/ReportsManualsForms/StaffPoliciesandProcedures/ucm073574.pd
f (setting out the charter for and duties of the IPRG). The FDA also has issued a decision tree for genomic
data submission. U.S. Food & Drug Admin., Guidance, supra, at 19.
[FN241]. Woodcock, supra note 135, at 93.
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